<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1803245058
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Daptomycin Amarox
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DAPTOMYCIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for solution for injection/infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        346.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ASPIRO PHARMA LIMITED" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ASPIRO PHARMA LIMITED
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2950]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01XX09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance in Daptomycin Amarox powder for injection is daptomycin. Daptomycin is an antibacterial that can stop the growth of certain bacteria. Daptomycin Amarox is used in adults and in children and adolescents (age from 1 to 17 years) to treat infections of the skin and the tissues below the skin. It is also used to treat infections in the blood when associated with skin infection.</p><p>&nbsp;</p><p>Daptomycin Amarox is also used in adults to treat infections in the tissues that line the inside of the heart (including heart valves) which are caused by a type of bacteria called Staphylococcus aureus. It is also used to treat infections in the blood caused by the same type of bacteria when associated with</p><p>&nbsp;</p><p>heart infection. Depending on the type of infection(s) that you have, your doctor may also prescribe other antibacterials while you are receiving treatment with Daptomycin Amarox.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You should not be given Daptomycin Amarox</strong></p><p>If you are allergic to daptomycin or to sodium hydroxide or to any of the other ingredients of this medicine (listed in section 6).</p><p>If this applies to you, tell your doctor or nurse. If you think you may be allergic, ask your doctor or nurse for advice.</p><p>Warnings and precautions</p><p>Talk to your doctor or nurse before you are given Daptomycin Amarox:</p><p>-&nbsp; If you have or have previously had kidney problems. Your doctor may need to change the dose of Daptomycin Amarox (see section 3 of this leaflet).</p><p>-&nbsp;&nbsp; Occasionally, patients receiving Daptomycin Amarox may develop tender or aching muscles or muscle weakness (see section 4 of this leaflet for more information). If this happens tell your doctor. Your doctor will make sure you have a blood test and will advise whether or not to continue with Daptomycin Amarox. The symptoms generally go away within a few days of stopping Daptomycin Amarox.</p><p>-&nbsp; If you have ever developed a severe skin rash or skin peeling, blistering and/or mouth sores, or serious kidney problems after taking daptomycin.</p><p>-&nbsp; If you are very overweight. There is a possibility that your blood levels of Daptomycin Amarox could be higher than those found in persons of average weight and you may need careful monitoring in case of side effects.</p><p>If any of these applies to you, tell your doctor or nurse before you are given Daptomycin Amarox .</p><p>&nbsp;</p><p>Tell your doctor or nurse straight away if you develop any of the following symptoms:</p><p><strong>&nbsp;</strong></p><p>-&nbsp;&nbsp;&nbsp; Serious, acute allergic reactions have been observed in patients treated with nearly all antibacterial agents, including Daptomycin Amarox. The symptoms can include wheezing, difficulty breathing, swelling of the face, neck and throat, rashes and hives, or fever.</p><p>-&nbsp; Serious skin disorders have been reported with the use of Daptomycin Amarox. The symptoms that occur with these skin disorders can include:</p><p>&nbsp;</p><p>-&nbsp; a new or worsening fever,</p><p>&nbsp;</p><p>-&nbsp;&nbsp; red raised or fluid-filled skin spots which may start in your armpits or on your chest or groin areas and which can spread over a large area of your body,</p><p>-&nbsp; blisters or sores in your mouth or on your genitals.</p><p>&nbsp;</p><p>-&nbsp;&nbsp; A serious kidney problem has been reported with the use of Daptomycin Amarox. The symptoms can include fever and rash.</p><p>-&nbsp;&nbsp; Any unusual tingling or numbness of the hands or feet, loss of feeling or difficulties with movements. If this happens, tell your doctor who will decide whether you should continue the treatment.</p><p>-&nbsp; Diarrhoea, especially if you notice blood or mucus, or if diarrhoea becomes severe or persistent.</p><p>&nbsp;</p><p>-&nbsp; New or worsening fever, cough or difficulty breathing. These may be signs of a rare but serious lung disorder called eosinophilic pneumonia. Your doctor will check the condition of your lungs and decide whether or not you should continue Daptomycin Amarox treatment.</p><p>Daptomycin Amarox may interfere with laboratory tests that measure how well your blood is clotting. The results can suggest poor blood clotting when, in fact, there is no problem. Therefore, it is important that your doctor takes into account that you are receiving Daptomycin Amarox. Please inform your doctor that you are on treatment with Daptomycin Amarox.</p><p>Your doctor will perform blood tests to monitor the health of your muscles both before you start treatment and frequently during treatment with Daptomycin Amarox.</p><p>Children and adolescents</p><p>&nbsp;</p><p>Daptomycin Amarox should not be administered to children below one year of age as&nbsp; studies in animals&nbsp; have indicated that this age group may experience severe side effects.</p><p>Use in elderly</p><p>&nbsp;</p><p>People over the age of 65 can be given the same dose as other adults, provided their kidneys are working well.</p><p>&nbsp;</p><p>Other medicines and Daptomycin Amarox</p><p>&nbsp;</p><p>Tell your doctor or nurse if you are taking, have recently taken or might take any other medicines. It is particularly important that you mention the following:</p><p>-&nbsp;&nbsp; Medicines called statins or fibrates (to lower cholesterol) or ciclosporin (a medicinal product used in transplantation to prevent organ rejection or for other conditions, e.g. rheumatoid arthritis or atopic dermatitis). It is possible that the risk of side effects affecting the muscles may be higher when any of these medicines (and some others that can affect muscles) is taken during treatment with Daptomycin Amarox. Your doctor may decide not to give you Daptomycin Amarox or to stop the other medicine for a while.</p><p>-&nbsp;&nbsp;&nbsp; Pain killing medicines called non-steroidal anti-inflammatory drugs (NSAIDs) or COX-2 inhibitors (e.g., celecoxib). These could interfere with the effects of Daptomycin Amarox in the kidney.</p><p>-&nbsp;&nbsp; Oral anti-coagulants (e.g., warfarin), which are medicines that prevent blood from clotting. It may be necessary for your doctor to monitor your blood clotting times.</p><p>Pregnancy and breast-feeding</p><p><strong>&nbsp;</strong></p><p>Daptomycin Amarox is not usually given to pregnant women. If&nbsp; you are pregnant or breast-feeding, think&nbsp; you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before you are given this medicine.</p><p>Do not breast-feed if you are receiving Daptomycin Amarox, because it may pass into your breast milk and could affect the baby.</p><p>Driving and using machines</p><p><strong>&nbsp;</strong></p><p>Daptomycin Amarox has no known effects on the ability to drive or use machines.</p><p>&nbsp;</p><p>Daptomycin Amarox contains sodium</p><p><strong>&nbsp;</strong></p><p>This medicine contains sodium that has to be taken into consideration by patients on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Daptomycin Amarox will usually be given to you by a doctor or a nurse. Adults (18 years of age and above)</p><p>The dose will depend on how much you weigh and the type of infection being treated. The usual dose for adults is 4 mg for every kilogram (kg) of body weight once daily for skin infections or 6 mg for every kg of body weight once daily for a heart infection or a blood infection associated with skin or heart infection. In adult patients, this dose is given directly into your blood stream (into a vein), either as an infusion lasting about 30 minutes or as an injection lasting about 2 minutes. The same dose is recommended in people aged over 65 years provided their kidneys are working well.</p><p>If your kidneys do not work well, you may receive Daptomycin Amarox less often, e.g. once every other&nbsp; day. If you are receiving dialysis, and your next dose of Daptomycin Amarox is due on a dialysis day, you will be usually given Daptomycin Amarox after the dialysis session.</p><p>Children and adolescents (1 to 17 years of age)</p><p>&nbsp;</p><p>The dose for children and adolescents (1 to 17 years of age) will depend on the age of patient and the type of infection being treated. This dose is given directly into the blood stream (into a vein), as an infusion lasting about 30-60 minutes.</p><p>A course of treatment usually lasts for 1 to 2 weeks for skin infections. For blood or heart infections and skin infections your doctor will decide how long you should be treated.</p><p>Detailed instructions for use and handling are given at the end of the leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The most serious side effects are described below:</p><p>Serious side effects with frequency not known (frequency cannot be estimated from the available data)</p><p>&nbsp;</p><p>-&nbsp; A hypersensitivity reaction (serious allergic reaction including anaphylaxis and angioedema) has been reported, in some cases during administration of Daptomycin. This serious allergic reaction needs immediate medical attention. Tell your doctor or nurse straight away if you experience any of the following symptoms:</p><p>-&nbsp; Chest pain or tightness,</p><p>&nbsp;</p><p>-&nbsp; Rash or hives,</p><p>&nbsp;</p><p>-&nbsp; Swelling around throat,</p><p>&nbsp;</p><p>-&nbsp; Rapid or weak pulse,</p><p>&nbsp;</p><p>-&nbsp; Wheezing,</p><p>&nbsp;</p><p>-&nbsp; Fever,</p><p>&nbsp;</p><p>-&nbsp; Shivering or trembling,</p><p>&nbsp;</p><p>-&nbsp; Hot flushes,</p><p>&nbsp;</p><p>-&nbsp; Dizziness,</p><p>&nbsp;</p><p>-&nbsp; Fainting,</p><p>&nbsp;</p><p>-&nbsp; Metallic taste.</p><p>&nbsp;</p><p>-&nbsp;&nbsp; Tell your doctor straight away if you experience unexplained muscle pain, tenderness, or weakness. Muscle problems can be serious, including muscle breakdown (rhabdomyolysis), which can result in kidney damage.</p><p>Other serious side effects that have been reported with the use of Daptomycin are:</p><p>&nbsp;</p><p>-&nbsp;&nbsp; A rare but potentially serious lung disorder called eosinophilic pneumonia, mostly after more than 2 weeks of treatment. The symptoms can include difficulty breathing, new or worsening cough, or new or worsening fever.</p><p>-&nbsp; Serious skin disorders. The symptoms can include:</p><p>&nbsp;</p><p>-&nbsp; a new or worsening fever,</p><p>&nbsp;</p><p>-&nbsp;&nbsp; red raised or fluid-filled skin spots which may start in your armpits or on your chest or groin areas and which can spread over a large area of your body,</p><p>-&nbsp; blisters or sores in your mouth or on your genitals.</p><p>&nbsp;</p><p>-&nbsp; A serious kidney problem. The symptoms can include fever and rash.</p><p>&nbsp;</p><p>If you experience these symptoms, tell your doctor or nurse straight away. Your doctor will perform additional tests to make a diagnosis.</p><p>The most frequently reported side effects are described below:</p><p>&nbsp;</p><p><strong>Common side effects </strong>(may affect up to 1 in 10 people)</p><p>&nbsp;</p><p>-&nbsp; Fungal infections such as thrush,</p><p>&nbsp;</p><p>-&nbsp; Urinary tract infection,</p><p>&nbsp;</p><p>-&nbsp; Decreased number of red blood cells (anaemia),</p><p>&nbsp;</p><p>-&nbsp; Dizziness, anxiety, difficulty in sleeping,</p><p>&nbsp;</p><p>-&nbsp; Headache,</p><p>&nbsp;</p><p>-&nbsp; Fever, weakness (asthenia),</p><p>&nbsp;</p><p>-&nbsp; High or low blood pressure,</p><p>&nbsp;</p><p>-&nbsp; Constipation, abdominal pain,</p><p>&nbsp;</p><p>-&nbsp; Diarrhoea, feeling sick (nausea) or being sick (vomiting),</p><p>&nbsp;</p><p>-&nbsp; Flatulence,</p><p>&nbsp;</p><p>-&nbsp; Abdominal swelling or bloating,</p><p>&nbsp;</p><p>-&nbsp; Skin rash or itching,</p><p>&nbsp;</p><p>-&nbsp; Pain, itchiness or redness at the site of infusion,</p><p>&nbsp;</p><p>-&nbsp; Pain in arms or legs,</p><p>&nbsp;</p><p>-&nbsp; Blood testing showing higher levels of liver enzymes or creatine phosphokinase (CPK). Other side effects which may occur following Daptomycin Amarox&nbsp;&nbsp; treatment are described below:</p><p><strong>Uncommon side effects </strong>(may affect up to 1 in 100 people)</p><p>&nbsp;</p><p>-&nbsp;&nbsp; Blood disorders (e.g. increased number of small blood particles called platelets, which may increase the tendency for blood clotting, or higher levels of certain types of white blood cells),</p><p>-&nbsp; Decreased appetite,</p><p>&nbsp;</p><p>-&nbsp; Tingling or numbness of the hands or feet, taste disturbance,</p><p>&nbsp;</p><p>-&nbsp; Trembling,</p><p>&nbsp;</p><p>-&nbsp; Changes in heart rhythm, flushes,</p><p>&nbsp;</p><p>-&nbsp; Indigestion (dyspepsia), inflammation of the tongue,</p><p>&nbsp;</p><p>-&nbsp; Itchy rash of skin,</p><p>&nbsp;</p><p>-&nbsp; Muscle pain, cramping, or weakness, inflammation of the muscles (myositis), joint pain,</p><p>&nbsp;</p><p>-&nbsp; Kidney problems,</p><p>&nbsp;</p><p>-&nbsp; Inflammation and irritation of the vagina,</p><p>&nbsp;</p><p>-&nbsp; General pain or weakness, tiredness (fatigue),</p><p>&nbsp;</p><p>-&nbsp;&nbsp; Blood test showing increased levels of blood sugar, serum creatinine, myoglobin, or lactate dehydrogenase (LDH), prolonged blood clotting time or imbalance of salts,</p><p>-&nbsp; Itchy eyes.</p><p>&nbsp;</p><p><strong>Rare side effects </strong>(may affect up to 1 in 1,000 people)</p><p>&nbsp;</p><p>-&nbsp; Yellowing of the skin and eyes</p><p>&nbsp;</p><p>-&nbsp; Prothrombin time prolonged.</p><p>&nbsp;</p><p><strong>Frequency not known </strong>(frequency cannot be estimated from the available data)</p><p>&nbsp;</p><p>Antibacterial-associated colitis, including pseudomembranous colitis (severe or persistent diarrhea containing blood and/or mucus, associated with abdominal pain or fever), easy bruising, bleeding gums, or nosebleeds.</p><p><u>Reporting of side effects</u></p><p>&nbsp;</p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions (see details below)</p><p>To report any side effect(s):</p><p>&nbsp;</p><p>&bull;&nbsp; <strong>Saudi Arabia:</strong></p><table border="1" cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; o Website: https://ade.sfda.gov.sa/</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States:</strong></p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in a refrigerator between 2&deg;C and 8&deg;C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Store this medicine in the original package and keep the bottle tightly closed in order to&nbsp; protect from moisture.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the carton after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Daptomycin Amarox contains</p><p>&nbsp;</p><p>The active substance is Daptomycin.</p><p>&nbsp;</p><p><strong>Daptomycin Amarox 350mg/vial</strong></p><p><strong>&nbsp;</strong></p><p>Each vial contains Daptomycin 350mg.</p><p>&nbsp;</p><p>The other ingredients are: Sodium Hydroxide and water for injection.</p><p>&nbsp;</p><p>Daptomycin Amarox 500mg/vial</p><p><strong>&nbsp;</strong></p><p>Each vial contains Daptomycin 500mg.</p><p>&nbsp;</p><p>The other ingredients are: Sodium Hydroxide and water for injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Daptomycin Amarox looks like?

Daptomycin Amarox 350mg/vial

Pale yellow to light brown, Lyophilized cake or powder.

Daptomycin Amarox 500mg/vial

Pale yellow to light brown, Lyophilized cake or powder.

How supplied:

Daptomycin Amarox Injections are supplied in tubular glass vials.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder and Manufacturer Saudi Amarox Industrial Company</p><p>Aljameah Street, Malaz quarter<br />Riyadh 12629, Saudi Arabia</p><p>Tel: +966 11 226 8850</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Manufacturer: </strong></p><p>Aspiro Pharma Limited, Hyderabad, India.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 2023 October, Version 1
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">المادة الفعالة في مسحوق دابتوميسين أماروكس للحقن هي دابتوميسين. دابتوميسين هو مضاد بكتيري يمكن أن يوقف نمو بعض البكتيريا. يستخدم دابتوميسين أماروكس في البالغين والأطفال والمراهقين (من 1 إلى 17 سنة) لعلاج التهابات الجلد والأنسجة تحت الجلد. كما أنها تستخدم لعلاج الالتهابات في الدم عندما تترافق مع عدوى الجلد.</p><p dir="RTL">يستخدم دابتوميسين أماروكس أيضًا عند البالغين لعلاج الالتهابات في الأنسجة التي تبطن القلب من الداخل (بما في ذلك صمامات القلب) والتي يسببها نوع من البكتيريا يسمى المكورات العنقودية الذهبية. كما أنه يستخدم لعلاج الالتهابات في الدم التي تسببها نفس النوع من البكتيريا عند ارتباطها بعدوى القلب. اعتمادًا على نوع العدوى التي تعاني منها، قد يصف لك طبيبك أيضًا مضادات بكتيرية أخرى أثناء تلقيك العلاج باستخدام دابتوميسين أماروكس.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم دابتوميسين أماروكس</strong></p><p dir="RTL">إذا كنت تعاني من حساسية تجاه دابتوميسين أو هيدروكسيد الصوديوم أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6).</p><p dir="RTL">إذا كان هذا ينطبق عليك، أخبر طبيبك أو ممرضتك. إذا كنت تعتقد أنك قد تكون مصابًا بالحساسية، فاطلب المشورة من طبيبك أو ممرضتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي أو الممرضة قبل تناول دابتوميسين أماروكس في الحالات التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني أو سبق أن عانيت من مشاكل في الكلى. قد يحتاج طبيبك إلى تغيير جرعة دابتوميسين أماروكس (انظر القسم 3 من هذه النشرة).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من حين لآخر، قد يصاب المرضى الذين يتلقون دابتوميسين أماروكس بألم أو آلام في العضلات أو ضعف في العضلات (انظر القسم 4 من هذه النشرة لمزيد من المعلومات). إذا حدث هذا أخبر طبيبك. سيتأكد طبيبك من إجراء فحص دم لك وسوف ينصحك بمواصلة دابتوميسين أماروكس أم لا. تختفي الأعراض بشكل عام في غضون أيام قليلة من إيقاف استخدام دابتوميسين أماروكس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أصبت في أي وقت مضى بطفح جلدي شديد أو تقشر الجلد، أو تقرحات و / أو تقرحات في الفم، أو مشاكل خطيرة في الكلى بعد تناول دابتوميسين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من السمنة المفرطة. هناك احتمال أن تكون مستويات دابتوميسين أماروكس في دمك أعلى من تلك الموجودة لدى الأشخاص ذوي الوزن المتوسط ​​، وقد تحتاج إلى مراقبة دقيقة في حالة الآثار الجانبية.</p><p dir="RTL">إذا كان أي من هذه الحالات ينطبق عليك، أخبر طبيبك أو ممرضتك قبل أن تتناول على دابتوميسين أماروكس.</p><p dir="RTL"><strong>أخبر طبيبك أو ممرضتك على الفور إذا ظهرت عليك أي من الأعراض التالية:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لوحظت تفاعلات حساسية خطيرة وحادة لدى المرضى الذين عولجوا تقريباً بجميع المواد المضادة للبكتيريا، بما في ذلك دابتوميسين أماروكس. يمكن أن تشمل الأعراض أزيزًا وصعوبة في التنفس وتورمًا في الوجه والرقبة والحلق والطفح الجلدي والشرى أو الحمى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تم الإبلاغ عن اضطرابات جلدية خطيرة عند استخدام دابتوميسين أماروكس. يمكن أن تشمل الأعراض التي تحدث مع هذه الاضطرابات الجلدية ما يلي:</p><p dir="RTL">حمى جديدة أو متفاقمة.</p><p dir="RTL">بقع جلدية حمراء بارزة أو مليئة بالسوائل والتي قد تبدأ في الإبطين أو على صدرك أو مناطق الفخذ والتي يمكن أن تنتشر على مساحة كبيرة من جسمك.</p><p dir="RTL">بثور أو تقرحات في فمك أو في أعضائك التناسلية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تم الإبلاغ عن مشكلة خطيرة في الكلى عند استخدام دابتوميسين أماروكس. يمكن أن تشمل الأعراض الحمى والطفح الجلدي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي وخز أو تنميل غير عادي في اليدين أو القدمين أو فقدان الإحساس أو صعوبات في الحركة. إذا حدث هذا، أخبر طبيبك الذي سيقرر ما إذا كان يجب عليك مواصلة العلاج.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال، خاصة إذا لاحظت وجود دم أو مخاط، أو إذا أصبح الإسهال شديدًا أو مستمرًا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى جديدة أو متفاقمة أو سعال أو صعوبة في التنفس. قد تكون هذه علامات لاضطراب رئوي نادر ولكنه خطير يسمى الالتهاب الرئوي اليوزيني. سيقوم طبيبك بفحص حالة رئتيك ويقرر ما إذا كان يجب عليك مواصلة علاج دابتوميسين أماروكس أم لا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يتداخل دابتوميسين أماروكس مع الاختبارات المعملية التي تقيس مدى جودة تخثر الدم. يمكن أن تشير النتائج إلى ضعف تخثر الدم في حين أنه في الواقع لا توجد مشكلة. لذلك، من المهم أن يأخذ طبيبك في الاعتبار أنك تتلقى دابتوميسين أماروكس. الرجاء إبلاغ طبيبك بأنك تتعالج باستخدام دابتوميسين أماروكس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيقوم طبيبك بإجراء فحوصات الدم لمراقبة صحة عضلاتك قبل بدء العلاج وبشكل متكرر أثناء العلاج باستخدام دابتوميسين أماروكس.</p><p dir="RTL"><strong>الأطفال والمراهقين</strong></p><p dir="RTL">لا ينبغي إعطاء دابتوميسين أماروكس للأطفال الذين تقل أعمارهم عن سنة واحدة حيث أشارت الدراسات التي أجريت على الحيوانات إلى أن هذه الفئة العمرية قد تعاني من آثار جانبية شديدة.</p><p dir="RTL"><strong>الاستخدام في حالة كبار السن</strong></p><p dir="RTL">يمكن إعطاء الأشخاص الذين تزيد أعمارهم عن 65 عامًا نفس الجرعة مثل البالغين الآخرين، بشرط التحقق من أن الكلى تعمل بشكل جيد.</p><p dir="RTL"><strong>الأدوية الأخرى ودابتوميسين أماروكس</strong></p><p dir="RTL">أخبر طبيبك أو ممرضتك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى. من المهم بشكل خاص أن تذكر ما يلي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية تسمى الستاتينات أو الفايبريت (لخفض الكوليسترول) أو سيكلوسبورين (منتج طبي يستخدم في حالات زرع الأعضاء لمنع رفض العضو أو لحالات أخرى، مثل التهاب المفاصل الروماتويدي أو التهاب الجلد التأتبي). من المحتمل أن تكون مخاطر الآثار الجانبية التي تؤثر على العضلات أعلى عند تناول أي من هذه الأدوية (وبعض الأدوية الأخرى التي يمكن أن تؤثر على العضلات) أثناء العلاج باستخدام دابتوميسين أماروكس. قد يقرر طبيبك عدم إعطائك دابتوميسين أماروكس أو إيقاف الدواء الآخر لفترة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المسكنة للألم والتي تسمى مضادات الالتهاب غير الستيرويدية (NSAIDs) أو مثبطات COX-2 (مثل السيليكوكسيب). يمكن أن تتداخل هذه مع تأثيرات دابتوميسين أماروكس في الكلى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات التخثر عن طريق الفم (مثل الوارفارين)، وهي أدوية تمنع الدم من التخثر. قد يكون من الضروري أن يقوم طبيبك بمراقبة أوقات تخثر الدم لديك.</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">عادة لا يعطى دابتوميسين أماروكس للحوامل. إذا كنت حاملاً أو مرضعة، تعتقدين أنك حامل أو تخططين لإنجاب طفل، استشيري طبيبك أو الصيدلي قبل إعطائك هذا الدواء.</p><p dir="RTL">لا ترضعي إذا كنت تتناولين دابتوميسين أماروكس ، لأنه قد ينتقل إلى حليب الثدي وقد يؤثر على الطفل.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">ليس دابتوميسين أماروكس تأثيرات معروفة على القدرة على القيادة أو استخدام الآلات.</p><p dir="RTL"><strong>محتوي دابتوميسين أماروكس من الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على الصوديوم الذي يجب أن يؤخذ في الاعتبار من قبل المرضى الذين يتبعون نظام غذائي بنسب محددة من الصوديوم.<strong> </strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">عادة ما يتم إعطاء دابتوميسين أماروكس لك من قبل طبيب أو ممرضة. الكبار (18 سنة وما فوق)</p><p dir="RTL">ستعتمد الجرعة على وزنك ونوع العدوى التي يتم علاجها. الجرعة المعتادة للبالغين هي 4 ملجرام لكل كيلو جرام من وزن الجسم مرة واحدة يوميًا للعدوى الجلدية أو 6 ملجرام لكل كيلو جرام من وزن الجسم مرة واحدة يوميًا لعدوى القلب أو عدوى الدم المرتبطة بالجلد أو عدوى القلب. في المرضى البالغين، تُعطى هذه الجرعة مباشرة في مجرى الدم (في الوريد)، إما على شكل تسريب يستمر حوالي 30 دقيقة أو كحقن يستمر حوالي دقيقتين. يوصى باستخدام نفس الجرعة للأشخاص الذين تزيد أعمارهم عن 65 عامًا بشرط التحقق من أن الكلى تعمل بشكل جيد.</p><p dir="RTL">إذا كانت الكليتان لا تعملان بشكل جيد، فقد تقل جرعة دابتوميسين أماروكس في كثير من الأحيان، على سبيل المثال مرة كل يومين. إذا كنت تخضع لغسيل الكلى، وكانت جرعتك التالية من دابتوميسين أماروكس مستحقة في يوم غسيل الكلى، فعادة ما يتم إعطاؤك دابتوميسين أماروكس بعد جلسة غسيل الكلى.</p><p dir="RTL">الأطفال والمراهقون (من 1 إلى 17 عامًا)</p><p dir="RTL">تعتمد الجرعة للأطفال والمراهقين (من 1 إلى 17 عامًا) على عمر المريض ونوع العدوى التي يتم علاجها. تُعطى هذه الجرعة مباشرة في مجرى الدم (في الوريد)، في شكل تسريب يستمر حوالي 30-60 دقيقة.</p><p dir="RTL">عادةً ما تستمر فترة العلاج من أسبوع إلى أسبوعين للعدوى الجلدية. بالنسبة لأمراض الدم أو القلب والتهابات الجلد، سيقرر طبيبك المدة التي يجب أن تعالج فيها.</p><p dir="RTL">تعليمات مفصلة للاستخدام والتعامل معروضة في نهاية النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، على الرغم من عدم حدوثها لدى الجميع. أخطر الآثار الجانبية موضحة أدناه:</p><p dir="RTL">أعراض جانبية خطيرة ذات شيوع غير معروف (لا يمكن تقدير معدلاتها من البيانات المتاحة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تم الإبلاغ عن تفاعل فرط الحساسية (رد فعل تحسسي خطير يشمل الحساسية المفرطة والوذمة الوعائية)، في بعض الحالات أثناء إعطاء دابتوميسين. يحتاج رد الفعل التحسسي الخطير هذا إلى عناية طبية فورية. أخبر طبيبك أو ممرضتك على الفور إذا واجهت أيًا من الأعراض التالية:</p><p dir="RTL">ألم أو ضيق في الصدر.</p><p dir="RTL">طفح جلدي أو خلايا.</p><p dir="RTL">تورم حول الحلق،</p><p dir="RTL">سرعة النبض أو ضعفها.</p><p dir="RTL">صفير،</p><p dir="RTL">حُمى،</p><p dir="RTL">ارتجاف،</p><p dir="RTL">الهبات الساخنة،</p><p dir="RTL">دوار،</p><p dir="RTL">إغماء،</p><p dir="RTL">طعم معدني.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر طبيبك على الفور إذا كنت تعاني من ألم عضلي غير مبرر أو رقة أو ضعف. يمكن أن تكون مشاكل العضلات خطيرة، بما في ذلك انهيار العضلات (انحلال الربيدات)، مما قد يؤدي إلى تلف الكلى.</p><p dir="RTL">الآثار الجانبية الخطيرة الأخرى التي تم الإبلاغ عنها باستخدام دابتوميسين هي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب رئوي نادر ولكنه قد يكون خطيرًا يسمى الالتهاب الرئوي اليوزيني، غالبًا بعد أكثر من أسبوعين من العلاج. يمكن أن تشمل الأعراض صعوبة في التنفس، أو سعال جديد أو متفاقم، أو حمى جديدة أو متفاقمة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات جلدية خطيرة. يمكن أن تشمل الأعراض:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى جديدة أو متفاقمة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بقع جلدية حمراء بارزة أو مليئة بالسوائل والتي قد تبدأ في الإبطين أو على صدرك أو مناطق الفخذ والتي يمكن أن تنتشر على مساحة كبيرة من جسمك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بثور أو تقرحات في فمك أو في أعضائك التناسلية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلة خطيرة في الكلى. يمكن أن تشمل الأعراض الحمى والطفح الجلدي.</p><p dir="RTL">إذا واجهت هذه الأعراض، أخبر طبيبك أو ممرضتك على الفور. سيقوم طبيبك بإجراء اختبارات إضافية لإجراء التشخيص.</p><p dir="RTL">الآثار الجانبية الأكثر شيوعًا التي تم الإبلاغ عنها موضحة أدناه:</p><p dir="RTL"><strong>أعراض جانبية شائعة (قد تظهر لدى حتى 1 من كل 10 أشخاص)</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الالتهابات الفطرية مثل مرض القلاع،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المسالك البولية،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم الحمراء (فقر الدم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوار وقلق وصعوبة في النوم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع الراس،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى والضعف (الوهن).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم أو انخفاضه.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمساك وآلام البطن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال والشعور بالغثيان أو التقيؤ.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ في البطن.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي أو حكة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أو حكة أو احمرار في مكان الحقن.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الذراعين أو الساقين،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أظهرت فحوصات الدم مستويات أعلى من إنزيمات الكبد أو فوسفوكيناز الكرياتين (CPK). الآثار الجانبية الأخرى التي قد تحدث بعد علاج دابتوميسين أماروكس موصوفة أدناه:</p><p dir="RTL"><strong>أعراض جانبية غير شائعة (قد تظهر لدى حتى 1 من كل 100 شخص)</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الدم (على سبيل المثال زيادة عدد جزيئات الدم الصغيرة التي تسمى الصفائح الدموية، والتي قد تزيد من الميل لتخثر الدم، أو مستويات أعلى لأنواع معينة من خلايا الدم البيضاء).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلة الشهية،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وخز أو تنميل في اليدين أو القدمين، اضطراب في التذوق،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتجاف،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في ضربات القلب، احمرار،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عسر الهضم والتهاب اللسان.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي وحكة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام العضلات، والتشنجات، أو الضعف، والتهاب العضلات، وآلام المفاصل،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الكلى،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب وتهيج المهبل.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أو ضعف عام، إرهاق (تعب).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أظهر فحص الدم زيادة مستويات السكر في الدم، أو كرياتينين الدم، أو الميوجلوبين، أو اللاكتات ديهيدروجينيز (LDH)، أو إطالة زمن تخثر الدم أو اختلال توازن الأملاح.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة في العيون.</p><p dir="RTL"><strong>أعراض جانبية نادرة (قد تظهر لدى حتى 1 من كل 1000 شخص)</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد والعينين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إطالة زمن البروثرومبين.</p><p dir="RTL"><strong>أعراض جانبية غير معروف معدلاتها (لا يمكن تقدير معدلاتها من البيانات المتاحة)</strong></p><p dir="RTL">التهاب القولون المرتبط بمضادات الجراثيم، بما في ذلك التهاب القولون الغشائي الكاذب (إسهال حاد أو مستمر يحتوي على دم و / أو مخاط، مرتبط بألم في البطن أو حمى)، كدمات بسيطة، نزيف اللثة، أو نزيف في الأنف.</p><p dir="RTL"><u>التبليغ عن الأعراض الجانبية</u></p><p dir="RTL">إذا عانيت من أي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي أو الممرضة. يتضمن ذلك أي آثار جانبية محتملة غير مذكورة في هذه النشرة. من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير مزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL"><u>الإبلاغ عن ردود الفعل السلبية المشتبه بها</u></p><p dir="RTL">من المهم الإبلاغ عن ردود الفعل السلبية المشتبه بها بعد الحصول على ترخيص من المنتج الطبي. يسمح بالمراقبة المستمرة لتوازن الفوائد / المخاطر للمنتج الطبي. يُطلب من المتخصصين في الرعاية الصحية الإبلاغ عن أي ردود فعل سلبية مشتبه بها (انظر التفاصيل أدناه)</p><p><strong>الإبلاغ عن الآثار الجانبية: </strong></p><p>إذا زادت حدة أي من هذه الأعراض الجانبية، أو لاحظت ظهور أعراض جانبية غير ما تم ذكره في هذه النشرة، يرجى إبلاغ الطبيب المعالج أو الصيدلي. وهذا يشمل أي آثار جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضا الإبلاغ عن الآثار الجانبية مباشرة (انظر التفاصيل أدناه). بالإبلاغ عن الآثار الجانبية يمكنك المساعدة في توفير مزيد من المعلومات حول أمان هذا الدواء.</p><p>&nbsp;</p><p><strong>للإبلاغ حول الأعراض الجانبية التي قد تحدث يرجى التواصل عبر العناوين التالية:</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية:</strong></p><table dir="rtl" border="0" cellspacing="0" cellpadding="0" style="width:553px"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ الدوائي (NPC)</p><ul><li dir="RTL">مركز الاتصال بالهيئة العامة للغذاء والدواء 19999:</li><li dir="RTL">البريد الإلكتروني npc.drug@sfda.gov.sa:</li><li dir="RTL">الموقع الإلكتروني: https://ade.sfda.gov.sa</li></ul></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دول الخليج العربي الأخرى:</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة.</p></td></tr></tbody></table><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احفظ هذا الدواء بعيدًا عن رؤية ومتناول أيدي الأطفال.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في الثلاجة بدرجة حرارة بين 2 و8 درجات مئوية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بتخزين هذا الدواء في العبوة الأصلية واحتفظ بالزجاجة مغلقة بإحكام من أجل الحماية من الرطوبة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة بعد EXP. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتخلص من الأدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ماذا تحتوي دابتوميسين أماروكس على:</strong></p><p dir="RTL">المادة الفعالة هي دابتوميسين</p><p dir="RTL"><strong>دابتوميسين أماروكس 350 ملجرام / زجاجة</strong></p><p dir="RTL">تحتوي كل زجاجة على دابتوميسين 350 ملجرام.</p><p dir="RTL">الصواغات الأخرى هي: هيدروكسيد الصوديوم وماء للحقن.</p><p dir="RTL"><strong>دابتوميسين أماروكس 500 ملجرام / زجاجة</strong></p><p dir="RTL">تحتوي كل زجاجة على دابتوميسين ٥٠٠ ملجرامم.</p><p dir="RTL">الصواغات الأخرى هي: هيدروكسيد الصوديوم وماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هو شكل </strong><strong>دابتوميسين أماروكس </strong><strong>؟</strong></p><p dir="RTL"><strong>دابتوميسين أماروكس 350 ملجرام / زجاجة</strong></p><p dir="RTL">مسحوق مجفف بالتجميد لونه أصفر شاحب إلى بني فاتح.</p><p dir="RTL"><strong>دابتوميسين أماروكس 500 ملجرام / زجاجة</strong></p><p dir="RTL">مسحوق مجفف بالتجميد لونه أصفر شاحب إلى بني فاتح.</p><p dir="RTL"><strong>&nbsp;</strong><strong>كيفية توفير </strong><strong>دابتوميسين أماروكس </strong><strong>؟</strong></p><p dir="RTL">يتم توفير الحقن في قوارير زجاجية أنبوبية الشكل.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p><strong>صاحب حق التسويق والشركة المصنعة:</strong></p><p dir="RTL"><strong>شركة اماروكس السعودية الصناعية</strong></p><p>شارع الجامعة ، الملز&nbsp; الرياض 12629</p><p>المملكة العربية السعودية.</p><p dir="RTL">تليفون: +966112268850</p><p dir="RTL"><strong>الشركة المصنعة: </strong></p><p dir="RTL">شركة أسبيرو فارما المحدودة، حيدرآباد، الهند</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة في أكتوبر 2023 ، نسخة 1 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Daptomycin Amarox (Daptomycin For Injection 350mg/vial and 500mg/vial)
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Daptomycin Amarox 350mg/vial
Each vial contains Daptomycin 350mg.
Daptomycin Amarox 500mg/vial
Each vial contains Daptomycin 500mg.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for solution for injection or infusion
Daptomycin Amarox (Daptomycin For Injection 350mg/vial and 500mg/vial) Pale yellow to light brown color, clear solution

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Daptomycin Amarox is indicated for the treatment of the following infections (see sections 4.4 and 5.1).</p><p>-&nbsp; Adult and paediatric (1 to 17 years of age) patients with complicated skin and soft-tissue infections (cSSTI).</p><p>-&nbsp;&nbsp; Adult patients with right-sided&nbsp; infective&nbsp; endocarditis&nbsp; (RIE)&nbsp; due&nbsp; to&nbsp; Staphylococcus&nbsp; aureus.&nbsp; It is recommended&nbsp; that&nbsp; thedecision&nbsp; to&nbsp; use&nbsp; daptomycin&nbsp; should&nbsp; take&nbsp;&nbsp; into&nbsp;&nbsp; account&nbsp;&nbsp; the antibacterial susceptibility of the organism and should bebased on expert advice. See sections 4.4 and</p><p>5.1.</p><p>-&nbsp; Adult and paediatric (1 to 17 years of age) patients with Staphylococcus aureus bacteraemia (SAB). In adults, use inbacteraemia should be associated with RIE or with cSSTI, while in paediatric patients, use in bacteraemia should beassociated with cSSTI.</p><p>Daptomycin is active against Gram positive bacteria only (see section 5.1). In mixed infections where Gram negativeand/or certain types of&nbsp; anaerobic&nbsp; bacteria&nbsp; are&nbsp; suspected, Daptomycin Amarox should be co-administered with appropriateantibacterial agent(s).</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical studies in patients employed infusion of daptomycin over at least 30 minutes. There is no clinical experience inpatients with the administration of daptomycin as an injection over 2 minutes. This mode of administration was onlystudied in healthy subjects. However, when compared with the same doses given as intravenous infusions over 30minutes there were no clinically important differences in the pharmacokinetics and safety profile of daptomycin (seealso sections 4.8 and 5.2).</p><p>Posology Adults</p><p>-&nbsp; cSSTI without concurrent SAB: Daptomycin Amarox 4 mg/kg is administered once every 24 hours for 7-14 days or until theinfection is resolved (see section 5.1).</p><p>-&nbsp;&nbsp; cSSTI with concurrent SAB: Daptomycin Amarox 6 mg/kg is administered once every 24 hours. See below for dose adjustments inpatients with renal impairment. The duration of therapy may need to</p><p>be longer than 14 days in accordance with theperceived risk of complications in the individual patient.</p><p>-&nbsp;&nbsp; Known or suspected RIE due to Staphylococcus aureus: Daptomycin Amarox 6 mg/kg is administered once every 24 hours. See below for dose adjustments in patients with renal impairment. The</p><p>duration of therapy should be in accordance withavailable official recommendations. Daptomycin Amarox is administered intravenously in 0.9 % sodium chloride (see section 6.6). Daptomycin Amarox should not be used morefrequently than once a day.</p><p>Creatine phosphokinase (CPK) levels must be measured at baseline and at regular intervals (at least weekly) duringtreatment (see section 4.4).</p><p>Renal impairment</p><p>Daptomycin is eliminated primarily by the kidney.</p><p>&nbsp;</p><p>Due to limited clinical experience (see table and footnotes below) Daptomycin&nbsp; Amarox&nbsp; should&nbsp; only be used in adult patients withany degree of renal impairment (CrCl &lt; 80 ml/min) when it is considered that the expected clinical benefit outweighsthe potential risk.&nbsp; The&nbsp; response&nbsp; to&nbsp; treatment, renal function and creatine phosphokinase (CPK) levels should be closelymonitored in all patients</p><p>&nbsp;</p><p>with any degree of renal impairment (see also sections 4.4 and 5.2)<em>. </em>The dosage regimen for Daptomycin Amarox in paediatric patients with renal impairment has not been established. Dose adjustments in adult patients with renal impairment by indication and creatinine clearance</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Indication for use</p></td><td style="vertical-align:top"><p>Creatinine clearance</p></td><td style="vertical-align:top"><p>Dose recommendation</p></td><td style="vertical-align:top"><p>Comments</p></td></tr><tr><td style="vertical-align:top"><p>cSSTI without SAB</p></td><td style="vertical-align:top"><p>&ge; 30 ml/min</p></td><td style="vertical-align:top"><p>4 mg/kg once daily</p></td><td style="vertical-align:top"><p>See section 5.1</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&lt; 30 ml/min</p></td><td style="vertical-align:top"><p>4 mg/kg every 48 hours</p></td><td style="vertical-align:top"><p>(1, 2)</p></td></tr><tr><td style="vertical-align:top"><p>RIE&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cSSTI associated with SAB</p></td><td style="vertical-align:top"><p>&ge; 30 ml/min</p></td><td style="vertical-align:top"><p>6 mg/kg once daily</p></td><td style="vertical-align:top"><p>See section 5.1</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&lt; 30 ml/min</p></td><td style="vertical-align:top"><p>6 mg/kg every 48 hours</p></td><td style="vertical-align:top"><p>(1, 2)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>cSSTI = complicated skin and soft-tissue infections; SAB = S. aureus bacteraemia</p><p>&nbsp;</p><p>(1)&nbsp; The safety and efficacy of the dose interval adjustment have not been evaluated in controlled clinical trials and the recommendation is based on pharmacokinetic studies and modelling results (see sections 4.4 and 5.2).</p><p>(2)&nbsp;&nbsp; The same dose adjustments, which are based on pharmacokinetic data in volunteers including PK modelling results, are recommended for adult patients on haemodialysis (HD) or continuous ambulatory peritoneal dialysis (CAPD). Whenever possible,&nbsp; Daptomycin&nbsp; Amarox&nbsp; should&nbsp; be&nbsp; administered&nbsp; following the completion of dialysis on dialysis days (see section 5.2).</p></td></tr></tbody></table><p>Hepatic impairment</p><p>No dose adjustment is necessary when administering Daptomycin Amarox to patients with mild or moderate hepatic impairment (Child-Pugh Class B) (see section 5.2). No&nbsp; data&nbsp; are&nbsp; available&nbsp; in patients with severe hepatic impairment (Child-PughClass C). Therefore caution should be exercised if Daptomycin Amarox is given to such patients.</p><p>Elderly patients</p><p>&nbsp;</p><p>The recommended doses should be used in elderly patients except those with severe renal impairment (see above andsection 4.4).</p><p>Paediatric population (1 to 17 years of age)</p><p>The recommended dosage regimens for paediatric patients based on age and indication are shown below.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Age Group</p></td><td colspan="4" style="vertical-align:top"><p>Indication</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>cSSTI without SAB</p></td><td colspan="2" style="vertical-align:top"><p>cSSTI associated with SAB</p></td></tr><tr><td style="vertical-align:top"><p>Dosage Regimen</p></td><td style="vertical-align:top"><p>Duration&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of Therapy</p></td><td style="vertical-align:top"><p>Dosage Regimen</p></td><td style="vertical-align:top"><p>Duration&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of Therapy</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>12 to 17 years</p></td><td style="vertical-align:top"><p>5 mg/kg once every 24 hours infused over 30 minutes</p></td><td rowspan="4" style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Up&nbsp;&nbsp;&nbsp;&nbsp; to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 14 days</p></td><td style="vertical-align:top"><p>7 mg/kg once every 24 hours infused over 30 minutes</p></td><td rowspan="4" style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>(1)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>7 to 11 years</p></td><td style="vertical-align:top"><p>7 mg/kg once every 24 hours infused over 30 minutes</p></td><td style="vertical-align:top"><p>9 mg/kg once every 24 hours infused over 30 minutes</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>2 to 6 years</p></td><td style="vertical-align:top"><p>9 mg/kg once every 24 hours infused over 60 minutes</p></td><td style="vertical-align:top"><p>12 mg/kg once every 24 hours infused over 60 minutes</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>1 to &lt; 2 years</p></td><td style="vertical-align:top"><p>10 mg/kg once every 24 hours infused over 60</p></td><td style="vertical-align:top"><p>12 mg/kg once every 24 hours infused over 60</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>minutes</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>minutes</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>cSSTI = complicated skin and soft-tissue infections; SAB = <em>S. aureus </em>bacteraemia;</p><p>&nbsp;</p><p>(1) Minimum duration of Daptomycin Amarox for paediatric SAB should be in accordance with the perceived risk of complications in the individual patient.</p><p>&nbsp;</p><p>The duration of Daptomycin Amarox may need to be longer than 14 days in accordance with the perceived risk of complications in the individual patient. In the paediatric SAB study, the mean duration of IV Daptomycin Amarox was 12 days, with a range of 1 to 44 days. The duration of therapy should be in accordance with available official recommendations.</p></td></tr></tbody></table><p>Daptomycin Amarox is administered intravenously in 0.9 % sodium chloride (see section 6.6).</p><p>Daptomycin Amarox should not be used morefrequently than once a day.</p><p>Creatine phosphokinase (CPK) levels must be measured at baseline and at regular intervals (at least weekly) during treatment (see section 4.4).</p><p>Paediatric patients below the age of one year should not be given Daptomycin Amarox due to the risk of potential effects onmuscular, neuromuscular and/or nervous systems (either peripheral and/or central) that were observed in neonatal dogs(see section 5.3).</p><p><u>Method of administration</u></p><p>In adults, Daptomycin Amarox is given by intravenous&nbsp; infusion&nbsp; (see&nbsp; section&nbsp; 6.6)&nbsp; and administered over a 30-minute period or byintravenous injection (see section 6.6) and administered over a 2-minute period.</p><p>In paediatric patients aged 7 to 17 years, Daptomycin Amarox is given by intravenous infusion over a 30-minute period (see section6.6). In paediatric patients aged 1 to 6 years, Daptomycin Amarox is given by intravenous infusion over a 60-minute period (seesection 6.6).</p><p>For instructions on reconstitution and dilution of the medicinal product before administration, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>General</p><p>If a focus of infection other than cSSTI or RIE is identified&nbsp; after&nbsp; initiation&nbsp; of&nbsp; Daptomycin Amarox therapy consideration should begiven to instituting alternative antibacterial therapy that has been demonstrated to be efficacious in the treatment of thespecific type of infection(s) present.</p><p><u>Anaphylaxis/hypersensitivity reactions</u></p><p>Anaphylaxis/hypersensitivity reactions have been reported with Daptomycin Amarox. If an allergic reaction to Daptomycin Amarox occurs, discontinue use and institute appropriate therapy.</p><p><u>Pneumonia</u></p><p>It has been demonstrated in clinical studies that Daptomycin Amarox is not effective in the treatment of pneumonia. Daptomycin Amarox is therefore not indicated for the treatment of pneumonia.</p><p><u>RIE due to Staphylococcus aureus</u></p><p>Clinical data on the use of Daptomycin Amarox to treat RIE due to Staphylococcus aureus are limited to 19 adult patients (see&ldquo;Clinical efficacy in adults&rdquo; in section&nbsp; 5.1).&nbsp; The&nbsp; safety&nbsp; and efficacy of Daptomycin Amarox in children and adolescents aged below18 years with right-sided infective endocarditis (RIE) due to Staphylococcus aureus have not been established.</p><p>The efficacy of Daptomycin Amarox in patients with prosthetic valve infections or with left-sided infective endocarditis due to Staphylococcus aureus has not been demonstrated.</p><p><u>Deep-seated infections</u></p><p>Patients with deep-seated infections should receive any required surgical interventions (e.g. debridement, removal ofprosthetic devices, valve replacement surgery) without delay. <u>Enterococcal</u> <u>infections</u></p><p>There is insufficient evidence to be able to draw any conclusions regarding the possible clinical efficacy of Daptomycin Amarox against infections due to enterococci, including Enterococcus faecalis and Enterococcus faecium. In addition, doseregimens of daptomycin that might be appropriate for the treatment of enterococcal infections, with or&nbsp; without&nbsp; bacteraemia,&nbsp; have&nbsp; not been identified. Failures with daptomycin in the treatment of enterococcal infections that were</p><p><u>&nbsp;&nbsp;mostly&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </u></p><p>&nbsp;</p><p>accompanied by bacteraemia have been reported. In some instances treatment failure has been associatedwith the selection of organisms with reduced susceptibility or frank resistance to daptomycin (see section 5.1).</p><p><u>Non-susceptible micro-organisms</u></p><p>The use of antibacterials may promote the overgrowth of non-susceptible micro-organisms. If superinfection occursduring therapy, appropriate measures should be taken.</p><p><u>Clostridioides difficile-associated diarrhoea</u></p><p>Clostridioides difficile-associated diarrhoea (CDAD)&nbsp; has&nbsp; been&nbsp; reported&nbsp; with&nbsp; Daptomycin Amarox (see section 4.8). If CDAD issuspected or confirmed, Daptomycin Amarox may need to be discontinued and appropriate treatment instituted as clinically indicated.</p><p><u>Drug/laboratory test interactions</u></p><p>False prolongation of prothrombin time (PT) and elevation of international normalised ratio (INR) have been observedwhen certain recombinant thromboplastin reagents are utilised for the assay (see also section 4.5).</p><p><u>Creatine phosphokinase and myopathy</u></p><p>Increases in plasma creatine phosphokinase (CPK; MM isoenzyme) levels associated with muscular pains&nbsp; and/or&nbsp; weakness&nbsp; and&nbsp; cases&nbsp; of&nbsp; myositis,&nbsp; myoglobinaemia&nbsp;&nbsp; and&nbsp; rhabdomyolysis&nbsp;&nbsp; have been reported during therapy with Daptomycin Amarox (see also sections 4.5, 4.8 and 5.3). In clinical studies, marked increases in plasma CPK to &gt; 5x Upper Limit ofNormal (ULN) without muscle symptoms occurred more commonly in Daptomycin Amarox-treated patients (1.9 %) than&nbsp;&nbsp; in those that received comparators (0.5 %). Therefore, it is recommended that:</p><p>&bull;&nbsp;&nbsp; Plasma CPK should be measured at baseline and at regular intervals (at least once weekly) during therapy in all patients.</p><p>&bull;&nbsp;&nbsp; CPK should be measured more frequently (e.g. every 2-3 days at least during the first two weeks of treatment) inpatients who are at higher risk of developing myopathy. For example, patients with any degree of renal impairment(creatinine clearance &lt; 80 ml/min; see also section 4.2), including those on haemodialysis or CAPD, and patients taking other medicinal products known to be associated with myopathy (e.g. HMG-CoA reductase inhibitors, fibratesand ciclosporin).</p><p>&bull;&nbsp;&nbsp; It cannot be ruled out that those patients with CPK greater than 5 times upper limit of normal at</p><p>&nbsp;</p><p>baseline may be at increased&nbsp; risk&nbsp; of&nbsp; further&nbsp; increases&nbsp; during&nbsp; daptomycin&nbsp; therapy.&nbsp; This&nbsp; should be taken into account when initiating daptomycin therapy and, if daptomycin is&nbsp; given,&nbsp; these&nbsp; patients should be monitored more frequently than once weekly.</p><p>&bull;&nbsp;&nbsp; Daptomycin Amarox should not be administered to patients who are taking other medicinal products associated with myopathyunless it is considered that the benefit to the patient outweighs the risk.</p><p>&bull;&nbsp;&nbsp;&nbsp; Patients should be reviewed regularly while on therapy for any signs or symptoms that might represent myopathy.</p><p>&bull;&nbsp;&nbsp; Any patient that develops unexplained muscle pain, tenderness, weakness or cramps should have CPK levelsmonitored every 2 days. Daptomycin Amarox should be discontinued in the presence of unexplained muscle symptoms if the CPKlevel reaches greater than 5 times upper limit of normal.<u> Peripheral neuropathy</u></p><p>Patients who develop signs or symptoms that might represent a peripheral neuropathy during therapy with Daptomycin Amarox should be investigated and consideration should be given to discontinuation of daptomycin (see sections 4.8 and 5.3).</p><p><u>Paediatric population</u></p><p>Paediatric patients below the age of one year should not be given Daptomycin Amarox due to the risk of potential effects onmuscular, neuromuscular, and/or nervous systems (either peripheral and/or central) that were observed in neonataldogs (see section 5.3).</p><p><u>Eosinophilic pneumonia</u></p><p>Eosinophilic pneumonia has been&nbsp; reported&nbsp; in&nbsp; patients&nbsp; receiving&nbsp; Daptomycin Amarox&nbsp; (see section 4.8). In most reported cases associated&nbsp; with&nbsp; Daptomycin Amarox,&nbsp; patients&nbsp; developed fever, dyspnoea with hypoxic respiratory insufficiency, and diffusepulmonary infiltrates or organising pneumonia. The majority of cases occurred after more than 2 weeks of treatment with Daptomycin Amarox and improved when Daptomycin Amarox was discontinued&nbsp; and steroid therapy was initiated. Recurrence&nbsp; of eosinophilic&nbsp; pneumonia&nbsp; upon&nbsp; re-exposure&nbsp; has&nbsp; been reported. Patients who develop these signs and symptoms while receiving Daptomycin Amarox should undergo prompt medical evaluation, including, if appropriate, bronchoalveolar lavage, to exclude othercauses (e.g. bacterial infection, fungal infection, parasites, other medicinal products).</p><p>&nbsp;</p><p>Daptomycin Amarox should be discontinued immediately and treatment with systemic steroids should be initiated when appropriate.</p><p><u>Severe cutaneous adverse reactions</u></p><p>Severe cutaneous adverse reactions (SCARs) including drug reaction with eosinophilia and systemic symptoms(DRESS) and vesiculobullous rash with or without mucous membrane involvement (Stevens-Johnson Syndrome (SJS)or Toxic Epidermal Necrolysis (TEN)), which could be life- threatening or fatal, have been reported with daptomycin (seesection 4.8). At the time of prescription, patients should be advised of the signs and symptoms of severe skinreactions, and be closely monitored. If signs and symptoms suggestive of these&nbsp; reactions&nbsp; appear,&nbsp; Daptomycin Amarox should be discontinued immediately and&nbsp; an alternative treatment should&nbsp; be considered.&nbsp; If the patient has developed a severecutaneous adverse reaction with the use of daptomycin,</p><p>treatment with daptomycin must not be restarted in thispatient at any time. <u>Tubulointerstitial nephritis</u></p><p>Tubulointerstitial nephritis (TIN) has been reported in post-marketing experience with daptomycin. Patients who developfever, rash, eosinophilia and/or new or worsening renal impairment while receiving Daptomycin Amarox should undergo medicalevaluation. If&nbsp; TIN&nbsp; is&nbsp; suspected, Daptomycin Amarox should be discontinued promptly and appropriate therapy and/or measuresshould be taken.</p><p><u>Renal impairment</u></p><p>Renal impairment has been reported during treatment with Daptomycin Amarox. Severe renal impairment may in itself also pre-dispose to elevations in daptomycin levels which may increase the risk of development of myopathy (see above).</p><p>An adjustment of Daptomycin Amarox dose interval&nbsp; is&nbsp; needed&nbsp; for&nbsp; adult&nbsp; patients whose&nbsp; creatinine clearance is &lt; 30 ml/min (seesections 4.2 and 5.2). The safety and efficacy of the dose interval adjustment have not been&nbsp; evaluated in&nbsp; controlled clinical trials and&nbsp; the recommendation&nbsp; is mainly based on pharmacokinetic modelling data. Daptomycin Amarox should only be used in such patients when it is considered that the expected clinical benefit outweighs the potential risk.</p><p>Caution is advised when administering Daptomycin Amarox to patients who already have some degree of renal impairment(creatinine clearance &lt; 80 ml/min) before commencing therapy with</p><p><u>&nbsp;&nbsp;Daptomycin Amarox.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </u></p><p>&nbsp;</p><p>Regular monitoring of renal function isadvised (see also section 5.2).</p><p>In addition, regular monitoring of renal function is advised during concomitant administration of potentially nephrotoxicagents, regardless of the patient&#39;s pre-existing renal function (see also section 4.5).</p><p>The dosage regimen for Daptomycin Amarox in paediatric patients with renal impairment has not been established.</p><p><u>Obesity</u></p><p>In obese subjects with Body Mass Index (BMI) &gt; 40 kg/m but with creatinine clearance &gt; 70 ml/min, the AUC daptomycin was significantly&nbsp; increased&nbsp; (mean&nbsp; 42&nbsp; %&nbsp; higher)&nbsp; compared&nbsp; with&nbsp; non- obese matched controls. There is limited information on the safety and efficacy of daptomycin in&nbsp;&nbsp; the very obese and so caution is recommended. However, there is currently no evidence that a dose reduction is required (see section 5.2).</p><p><u>Sodium</u></p><p>This medicine contains sodium that has to be taken into consideration by patients on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Daptomycin undergoes little to no Cytochrome P450 (CYP450)-mediated metabolism. It is unlikely that daptomycin will inhibit or induce the metabolism of medicinal products metabolised by the P450 system.</p><p>Interaction studies for Daptomycin Amarox&nbsp; were&nbsp; performed&nbsp; with&nbsp; aztreonam,&nbsp; tobramycin, warfarin and probenecid. Daptomycin had no effect on the pharmacokinetics of warfarin or probenecid, nor did these medicinal products alter thepharmacokinetics of daptomycin. The pharmacokinetics of daptomycin were not significantly altered by aztreonam.</p><p>Although small changes in the pharmacokinetics of daptomycin and tobramycin were observed during co-administrationby intravenous infusion over a 30-minute period using a Daptomycin Amarox dose of 2 mg/kg, the changes were not statistically significant. The interaction between daptomycin and tobramycin with an approved dose of Daptomycin Amarox is unknown.</p><p>Caution is warranted when Daptomycin Amarox is co-administered with tobramycin. Experience with the concomitant administration of Daptomycin Amarox and warfarin is limited.</p><p>&nbsp;</p><p>Studies of Daptomycin Amarox with anticoagulants other than&nbsp; warfarin&nbsp; have&nbsp; not&nbsp; been conducted. Anticoagulant activity in patients receiving Daptomycin Amarox and warfarin should be monitored for the first several days after therapy with Daptomycin Amarox is initiated.</p><p>There is limited experience regarding concomitant administration of daptomycin with other medicinal products that may trigger myopathy (e.g. HMG-CoA reductase inhibitors). However,&nbsp; some cases of marked rises in CPK levels and casesof rhabdomyolysis occurred in adult patients taking one of these medicinal products at the same time as Daptomycin Amarox. It is recommended that other medicinal&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; products&nbsp;&nbsp;&nbsp; associated&nbsp;&nbsp; with&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; myopathy should&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; possible&nbsp;&nbsp;&nbsp; be</p><p>temporarily discontinued during treatment with Daptomycin Amarox unless the benefits of concomitant administration outweigh the&nbsp; risk.&nbsp; If&nbsp; co-administrationcannot&nbsp; be&nbsp; avoided,&nbsp; CPK levels should be measured more frequently than once weekly and patients should be closely monitored for any signs or symptoms that might represent myopathy. See sections 4.4, 4.8 and 5.3. Daptomycin is primarily cleared by renal filtration and so plasma levels may be increased during co- administration with medicinal products that reduce renal filtration (e.g. NSAIDs and</p><p>COX-2 inhibitors). In addition, there is a potential for apharmacodynamic interaction to&nbsp; occur during co-administration due to additive renal effects. Therefore, caution is advised when daptomycin is co-administered with any other medicinal product known to reduce renal filtration. During post&ndash;marketing surveillance, cases of interference between daptomycin and particular reagents used in someassays of prothrombin time/international normalised ratio (PT/INR) have been reported. This interference led to a falseprolongation of PT and elevation of INR. If unexplained abnormalities of PT/INR are observed in patients takingdaptomycin, consideration should be given&nbsp; to a possible <em>in vitro </em>interaction with the laboratory test. The possibility of erroneous results</p><p>may be minimised by drawing samples for PT or INR testing near the time of trough plasmaconcentrations of daptomycin (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>No clinical data on pregnancies are available for daptomycin. Animal studies do not indicate direct or indirect harmfuleffects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3).</p><p>&nbsp;</p><p>&nbsp;</p><p>Daptomycin Amarox should not be used during pregnancy unless clearly necessary i.e., only if the expected benefit outweighs thepossible risk.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>In a single human case study, Daptomycin Amarox was intravenously administered daily for 28 days to a nursing mother at a dose of 500 mg/day, and samples of the patient&#39;s breast milk were collected over a 24-hour period on day 27. The highest measured concentration of daptomycin in the breast milk was 0.045 &mu;g/ml, which is a low concentration. Therefore, until more experience is gained, breast-feeding should be discontinued when Daptomycin Amarox is administered to nursing women.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>No clinical data on fertility are available for daptomycin. Animal studies do not indicate direct or indirect harmful effectswith respect to fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed.</p><p>On the basis of reported adverse drug reactions, Daptomycin Amarox is presumed to be unlikely to produce an effect on the abilityto drive or use machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile</p><p>&nbsp;</p><p>In clinical&nbsp; studies,&nbsp; 2,011&nbsp; adult&nbsp; subjects&nbsp; received&nbsp; Daptomycin Amarox.&nbsp; Within&nbsp; these&nbsp; trials,&nbsp; 1,221 subjects received a daily dose of 4mg/kg, of whom 1,108 were patients and 113 were healthy volunteers; 460 subjects received a daily dose of 6 mg/kg, of whom 304 were patients and</p><p>156 were healthy volunteers. In paediatric studies, 372 patients received Daptomycin Amarox, of whom 61 received a single dose and 311 received a therapeutic regimen for cSSTI or SAB (daily doses ranged from 4 mg/kgto 12 mg/kg).</p><p>&nbsp;</p><p>Adverse reactions (i.e. considered by the investigator to be possibly, probably, or definitely related to themedicinal product) were reported at similar frequencies for Daptomycin Amarox and comparator regimens.</p><p>&nbsp;</p><p>The most frequently reported adverse reactions (frequency common (&ge; 1/100 to &lt; 1/10)) are:</p><p>&nbsp;</p><p>Fungal infections, urinary tract infection, candida infection, anaemia, anxiety, insomnia, dizziness, headache,hypertension, hypotension,&nbsp; gastrointestinal&nbsp; and&nbsp; abdominal&nbsp; pain,&nbsp; nausea, &nbsp;vomiting, constipation, diarrhoea, flatulence,bloating and distension, liver function tests abnormal (increased alanine aminotransferase (ALT), aspartateaminotransferase (AST) or alkaline phosphatase (ALP)), rash, pruritus, limb pain, serum creatine phosphokinase (CPK)increased, infusion site reactions, pyrexia, asthenia.</p><p>Less frequently reported, but more serious, adverse reactions include hypersensitivity reactions, eosinophilicpneumonia (occasionally presenting as organising&nbsp; pneumonia),&nbsp; drug&nbsp; reaction&nbsp; with eosinophilia and systemicsymptoms (DRESS), angioedema and rhabdomyolysis.</p><p>Tabulated list of adverse reactions</p><p>&nbsp;</p><p>The following adverse reactions were reported during therapy and during follow-up with frequencies corresponding tovery common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000);very rare (&lt; 1/10,000); not known (cannot be estimated from the available data):</p><p>&nbsp;</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p>Table 1 Adverse reactions from clinical studies and post-marketing reports</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td colspan="6" style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Fungal infection</p></td><td style="vertical-align:top"><p>infections,</p></td><td style="vertical-align:top"><p>urinary</p></td><td style="vertical-align:top"><p>tract</p></td><td style="vertical-align:top"><p>infection,</p></td><td style="vertical-align:top"><p>candida</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td colspan="6" style="vertical-align:top"><p>Fungaemia</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Not known*:</p></td><td colspan="4" style="vertical-align:top"><p>Clostridioides difficile-associated diarrhoea**</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Blood&nbsp;&nbsp;&nbsp; and disorders</p></td><td rowspan="4" style="vertical-align:top"><p>lymphatic</p></td><td rowspan="4" style="vertical-align:top"><p>system</p></td><td style="vertical-align:top"><p>Common:</p></td><td colspan="4" style="vertical-align:top"><p>Anaemia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td colspan="4" style="vertical-align:top"><p>Thrombocythaemia,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; eosinophilia,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; international normalised ratio (INR) increased, leukocytosis</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td colspan="4" style="vertical-align:top"><p>Prothrombin time (PT) prolonged</p></td></tr><tr><td style="vertical-align:top"><p>Not known*:</p></td><td colspan="4" style="vertical-align:top"><p>Thrombocytopaenia</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Not known*:</p></td><td colspan="4" style="vertical-align:top"><p>Hypersensitivity**, manifested by isolated spontaneous reports including, but not limited to angioedema, pulmonary eosinophilia, sensation of oropharyngeal swelling, anaphylaxis**, infusion reactions including the following symptoms: tachycardia, wheezing, pyrexia, rigors, systemic flushing, vertigo, syncope and metallic taste</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism disorders</p></td><td style="vertical-align:top"><p>and</p></td><td style="vertical-align:top"><p>nutrition</p></td><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Decreased imbalance</p></td><td style="vertical-align:top"><p>appetite,</p></td><td style="vertical-align:top"><p>hyperglycaemia,</p></td><td style="vertical-align:top"><p>electrolyte</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Common:</p></td><td colspan="4" style="vertical-align:top"><p>Anxiety, insomnia</p></td></tr><tr><td colspan="3" rowspan="3" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Common:</p></td><td colspan="4" style="vertical-align:top"><p>Dizziness, headache</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td colspan="4" style="vertical-align:top"><p>Paraesthesia, taste disorder, tremor, eye irritation</p></td></tr><tr><td style="vertical-align:top"><p>Not known*:</p></td><td colspan="4" style="vertical-align:top"><p>Peripheral neuropathy**</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>Uncommon:</p></td><td colspan="4" style="vertical-align:top"><p>Vertigo</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Uncommon:</p></td><td colspan="4" style="vertical-align:top"><p>Supraventricular tachycardia, extrasystole</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" rowspan="2" style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Common:</p></td><td colspan="4" style="vertical-align:top"><p>Hypertension, hypotension</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td colspan="4" style="vertical-align:top"><p>Flushes</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thoracic mediastinal disorders</p></td><td style="vertical-align:top"><p>and</p></td><td style="vertical-align:top"><p>Not known*:</p></td><td colspan="4" style="vertical-align:top"><p>Eosinophilic pneumonia1**, cough</p></td></tr><tr><td colspan="2" rowspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Common:</p></td><td colspan="4" style="vertical-align:top"><p>Gastrointestinal and abdominal pain, nausea, vomiting, constipation, diarrhoea, flatulence, bloating and distension</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td colspan="4" style="vertical-align:top"><p>Dyspepsia, glossitis</p></td></tr><tr><td colspan="2" rowspan="2" style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Common:</p></td><td colspan="4" style="vertical-align:top"><p>Liver function tests abnormal2 (increased alanine aminotransferase (ALT), aspartate aminotransferase (AST) or alkaline phosphatase (ALP))</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td colspan="4" style="vertical-align:top"><p>Jaundice</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Skin and subcutaneous disorders</p></td><td rowspan="3" style="vertical-align:top"><p>tissue</p></td><td style="vertical-align:top"><p>Common:</p></td><td colspan="4" style="vertical-align:top"><p>Rash, pruritus</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td colspan="4" style="vertical-align:top"><p>Urticaria</p></td></tr><tr><td style="vertical-align:top"><p>Not known*:</p></td><td colspan="4" style="vertical-align:top"><p>Acute generalised exanthematous pustulosis (AGEP), drug reaction with eosinophilia and systemic symptoms (DRESS)**, vesiculobullous rash with or without mucous membrane involvement (SJS or TEN)**</p></td></tr><tr><td colspan="2" rowspan="2" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Limb&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain, (CPK)2 increased</p></td><td style="vertical-align:top"><p>serum</p></td><td style="vertical-align:top"><p>creatine</p></td><td style="vertical-align:top"><p>phosphokinase</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td colspan="4" style="vertical-align:top"><p>Myositis, increased myoglobin, muscular weakness, muscle pain, arthralgia, serum lactate dehydrogenase</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(LDH) increased, muscle cramps</p></td></tr><tr><td style="vertical-align:top"><p>Not known*:</p></td><td style="vertical-align:top"><p>Rhabdomyolysis3 **</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Renal impairment, including renal failure and renal insufficiency, serum creatinine increased</p></td></tr><tr><td style="vertical-align:top"><p>Not known*:</p></td><td style="vertical-align:top"><p>Tubulointerstitial nephritis (TIN)**</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Vaginitis</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>General&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disorders&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and administration site conditions</p></td><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Infusion site reactions, pyrexia, asthenia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Fatigue, pain</p></td></tr></tbody></table><p>* Based on post-marketing reports. Since these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency which is therefore categorised as not known.</p><p>** See section 4.4.</p><p>&nbsp;</p><p>1 While the exact incidence of eosinophilic pneumonia associated with daptomycin is unknown, to date the reporting rate of spontaneous reports is very low (&lt; 1/10,000).</p><p>2 In some cases of myopathy involving raised CPK and muscle symptoms, the patients also presented with elevated transaminases. These transaminase increases were likely to be related to the skeletal muscle effects. The majority of transaminase elevations were of Grade 1-3 toxicity and resolved upon discontinuation of treatment.</p><p>3 When clinical information on the patients was available to make a judgement, approximately 50 % of the cases occurred in patients with pre-existing renal impairment, or in those receiving concomitant medicinal products known to cause rhabdomyolysis.</p><p>&nbsp;</p><p>The safety data for the administration of daptomycin via 2-minute intravenous injection are derived from two pharmacokinetic studies in healthy adult volunteers. Based on these study results, both methods of daptomycin administration, the 2-minute intravenous injection and the 30-minute intravenous infusion, had a similar safety and tolerability profile. There was no relevant difference in local tolerability or in the nature and frequency of adverse reactions.</p><p>Reporting of suspected adverse reactions</p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions (see details below)</p><p>&bull;&nbsp; Saudi Arabia:</p><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
  margin-left:73.4pt;margin-top:12.4pt;width:402pt;height:99.75pt;z-index:-251655168;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:0in;margin-right:83.45pt;
     margin-bottom:0in;margin-left:13.45pt;margin-bottom:.0001pt;text-indent:
     -3.0pt;line-height:195%'><span style='letter-spacing:-.45pt'>The </span><span
     style='letter-spacing:-.3pt'>National </span><span style='letter-spacing:
     -.25pt'>Pharmacovigilance<span style='mso-spacerun:yes'>  </span></span><span
     style='letter-spacing:-.3pt'>and </span><span style='letter-spacing:-.4pt'>Drug<span
     style='mso-spacerun:yes'>  </span></span><span style='letter-spacing:-.25pt'>Safety<span
     style='mso-spacerun:yes'>  </span>Centre </span>(NPC) o SFDA Ca<b
     style='mso-bidi-font-weight:normal'>l </b><span style='letter-spacing:
     -.2pt'>Center:</span><span style='letter-spacing:1.8pt'> </span>19999<o:p></o:p></p>
     <p class=MsoBodyText style='margin-left:19.5pt;text-indent:-9.05pt;
     line-height:12.95pt;mso-line-height-rule:exactly;mso-list:l0 level1 lfo1;
     tab-stops:19.5pt'><![if !supportLists]><span style='letter-spacing:-1.1pt'><span
     style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
     </span></span></span><![endif]><span dir=LTR></span><a
     href="mailto:npc.drug@sfda.gov.sa"><span style='color:windowtext;
     letter-spacing:-.15pt;text-decoration:none;text-underline:none'>E-mail:npc.drug@sfda.gov.sa</span></a><o:p></o:p></p>
     <p class=MsoBodyText style='margin-left:0in'><span style='font-size:11.5pt;
     mso-bidi-font-size:12.0pt'><o:p>&nbsp;</o:p></span></p>
     <p class=MsoBodyText style='margin-left:19.5pt;text-indent:-9.05pt;
     mso-list:l0 level1 lfo1;tab-stops:19.5pt'><![if !supportLists]><span
     style='letter-spacing:-1.1pt'><span style='mso-list:Ignore'>o<span
     style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
     dir=LTR></span><span style='letter-spacing:-.15pt'>Website:https://ade.sfda.gov.sa/</span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="540" height="137" alt="Text Box: The National Pharmacovigilance  and Drug  Safety  Centre (NPC) o SFDA Cal Center: 19999
o	E-mail:npc.drug@sfda.gov.sa

o	Website:https://ade.sfda.gov.sa/
" src="file:///C:/Users/Lenovo/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>o Other GCC States:</strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the event of overdose, supportive care is advised. Daptomycin is slowly cleared from the body by haemodialysis(approximately 15 % of the administered dose is removed over 4 hours) or by peritoneal dialysis (approximately 11 % ofthe administered dose is removed over 48 hours).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antibacterials for systemic use, Other antibacterials, ATC code: J01XX09</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Daptomycin is a cyclic lipopeptide natural product that is active against Gram positive bacteria only. The mechanism of action involves binding (in the presence of calcium ions) to bacterial membranes of both growing andstationary phase cells causing depolarisation and leading to a rapid inhibition of protein, DNA, and RNA synthesis. Thisresults in bacterial cell death with negligible cell lysis.</p><p>PK/PD relationship</p><p>Daptomycin exhibits rapid, concentration dependent bactericidal activity against Gram positive organisms in vitro andin in vivo animal models. In animal models AUC/MIC and Cmax/MIC correlate with efficacy and predicted bacterial kill invivo at single doses equivalent to human adult doses of 4 mg/kg and 6 mg/kg once daily.</p><p>Mechanisms of resistance</p><p>Strains with decreased susceptibility to daptomycin have been reported especially during the treatment of patients withdifficult-to-treat infections and/or following administration for prolonged periods. In particular, there have been reports oftreatment failures in patients infected with Staphylococcus aureus, Enterococcus faecalis or Enterococcus faecium,including bacteraemic patients, that have been associated with the selection of organisms with reduced susceptibilityor frank resistance to daptomycin during therapy.</p><p>The mechanism(s) of daptomycin resistance is (are) not fully understood. Breakpoints</p><p>Minimum inhibitory concentration (MIC) breakpoint established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) for Staphylococci and Streptococci (except S. pneumoniae) are Susceptible &le; 1 mg/l and Resistant &gt; 1 mg/l.</p><p>Susceptibility</p><p>The prevalence of resistance may vary geographically and over time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Commonly Susceptible Species</strong></p></td></tr><tr><td style="vertical-align:top"><p>Staphylococcus aureus *</p></td></tr><tr><td style="vertical-align:top"><p>Staphylococcus haemolyticus</p></td></tr><tr><td style="vertical-align:top"><p>Coagulase negative staphylococci</p></td></tr><tr><td style="vertical-align:top"><p>Streptococcus agalactiae*</p></td></tr><tr><td style="vertical-align:top"><p>Streptococcus dysgalactiae subsp equisimilis*</p></td></tr><tr><td style="vertical-align:top"><p>Streptococcus pyogenes*</p></td></tr><tr><td style="vertical-align:top"><p>Group G streptococci</p></td></tr><tr><td style="vertical-align:top"><p>Clostridium perfringens</p></td></tr><tr><td style="vertical-align:top"><p>Peptostreptococcus spp</p></td></tr><tr><td style="vertical-align:top"><p><strong>Inherently resistant organisms</strong></p></td></tr><tr><td style="vertical-align:top"><p>Gram negative organisms</p></td></tr></tbody></table><p><strong>* </strong>denotes species against which it is considered that activity has been satisfactorily demonstrated in clinical studies.</p><p><u>Clinical efficacy in adults</u></p><p>In two adult clinical trials in complicated skin and soft&nbsp; tissues infections, 36 % of patients&nbsp; treated with Daptomycin Amarox met the criteria for&nbsp; systemic&nbsp; inflammatory&nbsp; response&nbsp; syndrome (SIRS). The most common type of infection treated was wound infection (38 % of patients), while 21 % had major abscesses. These limitations of the patients population treated should be taken into account when deciding to use Daptomycin Amarox.</p><p>In&nbsp;&nbsp;&nbsp; a&nbsp;&nbsp; randomised&nbsp;&nbsp; controlled&nbsp;&nbsp; open-label&nbsp;&nbsp;&nbsp; study&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 235&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; adult&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; patients&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with Staphylococcus aureus bacteraemia (i.e. at least one positive blood culture of Staphylococcus aureus prior to receiving the first dose) 19 of 120 patients treated with Daptomycin Amarox met the criteria for&nbsp; RIE. Of these 19 patients 11 were infected with methicillin-susceptible and 8 with methicillin- resistant Staphylococcus aureus. The success rates in RIE patients are shown in the table below.</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Population</strong></p></td><td style="vertical-align:top"><p><strong>Daptomycin</strong></p></td><td style="vertical-align:top"><p><strong>Comparator</strong></p></td><td style="vertical-align:top"><p><strong>Differences in Success</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>n/N (%)</strong></p></td><td style="vertical-align:top"><p><strong>n/N (%)</strong></p></td><td style="vertical-align:top"><p><strong>Rates (95 % CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p>ITT (intention to treat) Population</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>RIE</p></td><td style="vertical-align:top"><p>8/19 (42.1 %)</p></td><td style="vertical-align:top"><p>7/16 (43.8 %)</p></td><td style="vertical-align:top"><p>-1.6 % (-34.6, 31.3)</p></td></tr><tr><td style="vertical-align:top"><p>PP (per protocol) Population</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>RIE</p></td><td style="vertical-align:top"><p>6/12 (50.0 %)</p></td><td style="vertical-align:top"><p>4/8 (50.0 %)</p></td><td style="vertical-align:top"><p>0.0 % (-44.7, 44.7)</p></td></tr></tbody></table><p>Failure of treatment due to persisting or relapsing Staphylococcus aureus infections was observed in 19/120 (15.8 %) patients treated with Daptomycin Amarox, 9/53 (16.7 %) patients treated with vancomycin and 2/62 (3.2 %) patients treated with an anti-staphylococcal semi-synthetic penicillin. Among these failures six patients treated with Daptomycin Amarox and one patient treated with vancomycin&nbsp;&nbsp; were infected&nbsp; &nbsp;with Staphylococcus&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aureus that developed increasing MICs of daptomycin on or following therapy (see &ldquo;Mechanisms of resistance&rdquo; above). Most patients who failed due to persisting or relapsing Staphylococcus aureus infection had deep-seated infection and did not receive necessary surgical intervention.</p><p><u>Clinical efficacy in paediatric patients</u></p><p>The safety and efficacy of daptomycin was evaluated in paediatric patients aged 1 to 17 years (Study DAP-PEDS-07-03) with cSSTI caused by Gram positive pathogens. Patients were enrolled in a stepwise approach into well-defined age groups and given age-dependent doses once daily for up to 14 days, as follows:</p><p>&bull;&nbsp; Age group 1 (n=113): 12 to 17 years treated with daptomycin dosed at 5 mg/kg or standard-of-care comparator (SOC);</p><p>&bull;&nbsp; Age group 2 (n=113): 7 to 11 years treated with daptomycin dosed at 7 mg/kg or SOC;</p><p>&bull;&nbsp; Age group 3 (n=125): 2 to 6 years treated with daptomycin dosed at 9 mg/kg or SOC;</p><p>&bull;&nbsp; Age group 4 (n=45): 1 to &lt; 2 years treated with daptomycin dosed at 10 mg/kg or SOC.</p><p>The primary objective of Study DAP-PEDS-07-03 was to assess the safety of treatment. Secondary objectives included an assessment of efficacy of age-dependent doses of intravenous daptomycin in comparison with standard-of-care therapy. The key efficacy endpoint was the sponsor-defined clinical outcome at test-of-cure (TOC), which was defined by a blinded medical director. A total of</p><p>&nbsp;</p><p>389 subjects were treated in the study, including 256 subjects who received daptomycin and 133 subjects who received standard-of-care. In all populations the clinical success rates were comparable between the daptomycin and SOC treatment arms, supporting the primary efficacy analysis in the ITT population.</p><p>&nbsp;</p><p>Summary of sponsor-defined clinical outcome at TOC:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Clinical Success in Paediatric cSSTI</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Daptomycin n/N (%)</strong></p></td><td style="vertical-align:top"><p><strong>Comparator n/N (%)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p><strong>% difference</strong></p></td></tr><tr><td style="vertical-align:top"><p>Intent-to-treat</p></td><td style="vertical-align:top"><p>227/257 (88.3 %)</p></td><td style="vertical-align:top"><p>114/132 (86.4 %)</p></td><td style="vertical-align:top"><p>2.0</p></td></tr><tr><td style="vertical-align:top"><p>Modified intent-to-treat</p></td><td style="vertical-align:top"><p>186/210 (88.6 %)</p></td><td style="vertical-align:top"><p>92/105 (87.6 %)</p></td><td style="vertical-align:top"><p>0.9</p></td></tr><tr><td style="vertical-align:top"><p>Clinically evaluable</p></td><td style="vertical-align:top"><p>204/207 (98.6 %)</p></td><td style="vertical-align:top"><p>99/99 (100 %)</p></td><td style="vertical-align:top"><p>-1.5</p></td></tr><tr><td style="vertical-align:top"><p>Microbiologically evaluable (ME)</p></td><td style="vertical-align:top"><p>164/167 (98.2 %)</p></td><td style="vertical-align:top"><p>78/78 (100 %)</p></td><td style="vertical-align:top"><p>-1.8</p></td></tr></tbody></table><p>The overall therapeutic response rate also was similar for the daptomycin and SOC treatment arms for infections caused by MRSA, MSSA and Streptococcus pyogenes (see table below; ME population); response rates were &gt; 94 % for both treatment arms across these common pathogens.</p><p>Summary of overall therapeutic response by type of baseline pathogen (ME population):</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p><p><strong>Pathogen</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Overall Success</strong>a <strong>rate in Paediatric cSSTI</strong></p><p><strong>n/N (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Daptomycin</strong></p></td><td style="vertical-align:top"><p><strong>Comparator</strong></p></td></tr><tr><td style="vertical-align:top"><p>Methicillin-susceptible Staphylococcus aureus (MSSA)</p></td><td style="vertical-align:top"><p>68/69 (99 %)</p></td><td style="vertical-align:top"><p>28/29 (97 %)</p></td></tr><tr><td style="vertical-align:top"><p>Methicillin-resistant Staphylococcus aureus (MRSA)</p></td><td style="vertical-align:top"><p>63/66 (96 %)</p></td><td style="vertical-align:top"><p>34/34 (100 %)</p></td></tr><tr><td style="vertical-align:top"><p>Streptococcus pyogenes</p></td><td style="vertical-align:top"><p>17/18 (94 %)</p></td><td style="vertical-align:top"><p>5/5 (100 %)</p></td></tr></tbody></table><p>a Subjects achieving clinical success (Clinical Response of &ldquo;Cure&rdquo; or &ldquo;Improved&rdquo;) and microbiological success (pathogen&ndash;level response of &ldquo;Eradicated&rdquo; or &ldquo;Presumed Eradicated&rdquo;) are classified as overall therapeutic success.</p><p>&nbsp;</p><p>The safety and efficacy of daptomycin was evaluated in paediatric patients aged 1 to 17 years (Study DAP-PEDBAC-11-02) with bacteraemia caused by <em>Staphylococcus aureus</em>. Patients were randomised in a 2:1 ratio into the following age groups and given age-dependent doses once daily for up to 42 days, as follows:</p><p>&bull;&nbsp; Age group 1 (n=21): 12 to 17 years treated with daptomycin dosed at 7 mg/kg or SOC comparator;</p><p>&bull;&nbsp; Age group 2 (n=28): 7 to 11 years treated with daptomycin dosed at 9 mg/kg or SOC;</p><p>&bull;&nbsp; Age group 3 (n=32): 1 to 6 years treated with daptomycin dosed at 12 mg/kg or SOC;</p><p>The primary objective of Study DAP-PEDBAC-11-02 was to assess the safety of intravenous daptomycin versus SOC antibiotics. Secondary objectives included: Clinical outcome based on the blinded Evaluator&#39;s assessment of clinical response (success [cure, improved], failure, or non- evaluable) at the TOC Visit; and Microbiological response (success, failure, or non-evaluable) based on evaluation of Baseline infecting pathogen at TOC.</p><p>A total of 81 subjects were treated in the study, including 55 subjects who received daptomycin and 26 subjects who received standard-of-care. No patients 1 to &lt;2 years of age were enrolled in the study. In all populations the clinical success rates were comparable in the daptomycin versus the SOC treatment arm.</p><p>Summary of Blinded Evaluator defined clinical outcome at TOC:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Clinical Success in Paediatric SAB</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Daptomycin n/N (%)</strong></p></td><td style="vertical-align:top"><p><strong>Comparator n/N (%)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p><strong>% difference</strong></p></td></tr><tr><td style="vertical-align:top"><p>Modified intent-to-treat (MITT)</p></td><td style="vertical-align:top"><p>46/52 (88.5 %)</p></td><td style="vertical-align:top"><p>19/24 (79.2 %)</p></td><td style="vertical-align:top"><p>9.3 %</p></td></tr><tr><td style="vertical-align:top"><p>Microbiologically modified intent- to-treat (mMITT)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>45/51 (88.2 %)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>17/22 (77.3 %)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>11.0 %</p></td></tr><tr><td style="vertical-align:top"><p>Clinically evaluable (CE)</p></td><td style="vertical-align:top"><p>36/40 (90.0 %)</p></td><td style="vertical-align:top"><p>9/12 (75.0 %)</p></td><td style="vertical-align:top"><p>15.0 %</p></td></tr></tbody></table><p>The microbiological outcome at TOC for the daptomycin and SOC treatment arms for infections caused by MRSA and MSSA are presented in the table below (mMITT population).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Pathogen</strong></p></td><td style="vertical-align:top"><p><strong>Microbiological Success rate in Paediatric</strong></p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>SAB</strong></p><p><strong>n/N (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Daptomycin</strong></p></td><td style="vertical-align:top"><p><strong>Comparator</strong></p></td></tr><tr><td style="vertical-align:top"><p>Methicillin-susceptible Staphylococcus aureus (MSSA)</p></td><td style="vertical-align:top"><p>43/44 (97.7 %)</p></td><td style="vertical-align:top"><p>19/19 (100.0 %)</p></td></tr><tr><td style="vertical-align:top"><p>Methicillin-resistant Staphylococcus aureus (MRSA)</p></td><td style="vertical-align:top"><p>6/7 (85.7 %)</p></td><td style="vertical-align:top"><p>3/3 (100.0 %)</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Daptomycin pharmacokinetics are generally linear and time-independent at doses of 4 to 12 mg/kg administered as a single daily dose by 30-minute intravenous infusion for up to 14 days in healthy adult volunteers. Steady-state concentrations are achieved by the third daily dose.</p><p>Daptomycin administered as a 2-minute intravenous injection also exhibited dose proportional pharmacokinetics in the approved therapeutic dose range of 4 to 6 mg/kg. Comparable exposure (AUC and Cmax) was demonstrated in healthy adult subjects following administration of daptomycin as a 30-minute intravenous infusion or as a 2-minute intravenous injection.</p><p>Animal studies showed that daptomycin is not absorbed to any significant extent after oral administration.</p><p>Distribution</p><p>The volume of distribution at steady state of daptomycin in healthy adult subjects was approximately</p><p>0.1 l/kg and wasindependent of dose. Tissue distribution studies in rats showed that daptomycin appears to only minimally penetratethe blood-brain barrier and the placental barrier following single and multiple doses.</p><p>Daptomycin is reversibly bound to human plasma proteins in a concentration independent manner. In healthy adultvolunteers and adult patients treated with daptomycin, protein binding averaged about 90 % including subjects withrenal impairment.</p><p>Biotransformation</p><p>In in vitro studies, daptomycin was not metabolised by human liver microsomes. In vitro studies with humanhepatocytes indicate that daptomycin does not inhibit or induce the activities of the following human cytochrome P450isoforms: 1A2, 2A6, 2C9, 2C19, 2D6, 2E1 and 3A4. It is unlikely that</p><p>&nbsp;</p><p>daptomycin will inhibit or induce the metabolismof medicinal products metabolised by the P450 system.</p><p>After infusion of 14C-daptomycin in healthy adults, the plasma radioactivity was similar to the concentration determinedby microbiological assay. Inactive metabolites were detected in urine, as determined by the difference in totalradioactive concentrations and microbiologically active concentrations. In a separate study, no metabolites wereobserved in plasma, and minor amounts of three oxidative metabolites and one unidentified compound were detected inurine. The site of metabolism has not been identified.</p><p>Elimination</p><p>Daptomycin is excreted primarily by the kidneys. Concomitant administration of probenecid and daptomycin has noeffect on daptomycin pharmacokinetics in humans suggesting minimal to no active tubular secretion of daptomycin.</p><p>Following intravenous administration, plasma clearance of daptomycin is approximately 7 to 9 ml/hr/kg and its renalclearance is 4 to 7 ml/hr/kg.</p><p>In a mass balance study using radiolabelled material, 78 % of the administered dose was recovered from the urinebased on total radioactivity, whilst urinary recovery of unchanged daptomycin was approximately 50 % of the dose.About 5 % of the administered radiolabel was excreted in the faeces. <u>Special populations</u></p><p>Elderly</p><p>Following administration of a single 4 mg/kg intravenous dose of Daptomycin Amarox over a 30- minute period, the mean totalclearance of daptomycin was approximately 35 % lower and the&nbsp;&nbsp; mean AUC</p><p>was approximately 58 % higher inelderly subjects (&ge; 75 years of age) compared with those in healthy young subjects (18 to 30 years of age). There wereno differences in Cmax. The differences noted are most likely due to the normal reduction in renal function observed inthe geriatric population.</p><p>No dose adjustment is necessary based on age alone. However, renal function should be assessed and the dose should be reduced if there is evidence of severe renal impairment.</p><p>Children and adolescents (1 to 17 years of age)</p><p>&nbsp;</p><p>The pharmacokinetics of daptomycin in&nbsp; paediatric&nbsp; subjects&nbsp; was&nbsp; evaluated&nbsp; in&nbsp; 3&nbsp; single-dose pharmacokinetic studies.After a single 4 mg/kg dose of Daptomycin Amarox, total clearance normalised by weight and elimination half-life of daptomycin inadolescents (12-17 years of age) with Gram-positive infection were similar to adults. After a single 4 mg/kg dose of Daptomycin Amarox, total clearance of daptomycin in children 7-11 years of age with Gram-positive infection was&nbsp; higher&nbsp; than inadolescents, whereas&nbsp; elimination half-life&nbsp; was shorter.&nbsp; After&nbsp; a single 4, 8, or 10 mg/kg dose of Daptomycin Amarox, total clearanceand elimination half-life of daptomycin in children 2-6 years of age were similar at different doses; total clearance was higher and elimination half-life was shorter than in adolescents. After a single 6 mg/kg dose of Daptomycin Amarox, the clearanceand elimination half-life of daptomycin in children 13-24 months of age were similar to children 2-6&nbsp; years of age whoreceived a single 4-10 mg/kg dose. The results&nbsp;&nbsp;&nbsp; of these studies show that exposures (AUC) in paediatric patients across all doses are generally lower than those in adults at comparable doses.</p><p>Paediatric patients with cSSTI</p><p>A Phase 4 study (DAP-PEDS-07-03) was conducted to assess safety, efficacy, and pharmacokinetics of daptomycin inpaediatric patients (1 to 17 years old, inclusive) with cSSTI caused by Gram-positive pathogens. Daptomycin pharmacokinetics in patients in this study are summarised in Table 2</p><p>Following administration of multiple doses,daptomycin exposure&nbsp; was&nbsp; similar&nbsp; across&nbsp; different age groups after dose adjustment based on body weight and age.Plasma exposures achieved with these doses were consistent with those achieved in the adult cSSTI study (following 4mg/kg once daily in adults).</p><p>Table 2 Mean (Standard Deviation) of Daptomycin Pharmacokinetics in Paediatric cSSTI Patients (1 to 17 Years of Age) in Study DAP-PEDS-07-03</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Age Range</p></td><td style="vertical-align:top"><p>12-17 years (N=6)</p></td><td style="vertical-align:top"><p>7-11 years (N=2)a</p></td><td style="vertical-align:top"><p>2-6 years (N=7)</p></td><td style="vertical-align:top"><p>1&nbsp;&nbsp;&nbsp;&nbsp; to&nbsp;&nbsp;&nbsp;&nbsp; &lt;2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; years (N=30)b</p></td></tr><tr><td style="vertical-align:top"><p>Dose</p><p>Infusion Time</p></td><td style="vertical-align:top"><p>5 mg/kg</p><p>30 minutes</p></td><td style="vertical-align:top"><p>7 mg/kg</p><p>30 minutes</p></td><td style="vertical-align:top"><p>9 mg/kg</p><p>60 minutes</p></td><td style="vertical-align:top"><p>10 mg/kg</p><p>60 minutes</p></td></tr><tr><td style="vertical-align:top"><p>AUC0-24hr</p></td><td style="vertical-align:top"><p>387 (81)</p></td><td style="vertical-align:top"><p>438</p></td><td style="vertical-align:top"><p>439 (102)</p></td><td style="vertical-align:top"><p>466</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>(&mu;g&times;hr/ml)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cmax (&mu;g/ml)</p></td><td style="vertical-align:top"><p>62.4 (10.4)</p></td><td style="vertical-align:top"><p>64.9, 74.4</p></td><td style="vertical-align:top"><p>81.9 (21.6)</p></td><td style="vertical-align:top"><p>79.2</p></td></tr><tr><td style="vertical-align:top"><p>Apparent t1/2 (hr)</p></td><td style="vertical-align:top"><p>5.3 (1.6)</p></td><td style="vertical-align:top"><p>4.6</p></td><td style="vertical-align:top"><p>3.8 (0.3)</p></td><td style="vertical-align:top"><p>5.04</p></td></tr><tr><td style="vertical-align:top"><p>CL/wt (ml/hr/kg)</p></td><td style="vertical-align:top"><p>13.3 (2.9)</p></td><td style="vertical-align:top"><p>16.0</p></td><td style="vertical-align:top"><p>21.4 (5.0)</p></td><td style="vertical-align:top"><p>21.5</p></td></tr></tbody></table><p>Pharmacokinetic parameter values estimated by noncompartmental analysis</p><p>aIndividual values reported as only two patients in this age group provided pharmacokinetic samples to enable pharmacokinetic analysis; AUC, apparent t1/2 and CL/wt could be determined for only one of the two patients</p><p>bPharmacokinetic analysis conducted on the pooled pharmacokinetic profile with mean</p><p>concentrations across subjects at each time point Paediatric patients with SAB</p><p>A Phase 4 study (DAP-PEDBAC-11-02) was conducted to assess safety, efficacy, and pharmacokinetics of daptomycin in paediatric patients (1 to 17 years old, inclusive) with SAB. Daptomycin pharmacokinetics inpatients in this study are summarised in Table 3. Following administration of multiple doses, daptomycin exposure was similar across different age groups after dose adjustment based on body weight and age. Plasma exposures achieved with these doses were consistent with those achieved in the adult SAB study (following 6 mg/kg once daily in adults).</p><p>Table 3 Mean (Standard Deviation) of Daptomycin Pharmacokinetics in Paediatric SAB Patients (1 to 17 Years of Age) in Study DAP-PEDBAC-11-02</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Age Range</p></td><td style="vertical-align:top"><p>12-17 years (N=13)</p></td><td style="vertical-align:top"><p>7-11 years (N=19)</p></td><td style="vertical-align:top"><p>1 to 6 years (N=19)*</p></td></tr><tr><td style="vertical-align:top"><p>Dose</p><p>Infusion Time</p></td><td style="vertical-align:top"><p>7 mg/kg</p><p>30 minutes</p></td><td style="vertical-align:top"><p>9 mg/kg</p><p>30 minutes</p></td><td style="vertical-align:top"><p>12 mg/kg</p><p>60 minutes</p></td></tr><tr><td style="vertical-align:top"><p>AUC0-24hr</p><p>(&mu;g&times;hr/ml)</p></td><td style="vertical-align:top"><p>656 (334)</p></td><td style="vertical-align:top"><p>579 (116)</p></td><td style="vertical-align:top"><p>620 (109)</p></td></tr><tr><td style="vertical-align:top"><p>Cmax (&mu;g/ml)</p></td><td style="vertical-align:top"><p>104 (35.5)</p></td><td style="vertical-align:top"><p>104 (14.5)</p></td><td style="vertical-align:top"><p>106 (12.8)</p></td></tr><tr><td style="vertical-align:top"><p>Apparent t1/2 (hr)</p></td><td style="vertical-align:top"><p>7.5 (2.3)</p></td><td style="vertical-align:top"><p>6.0 (0.8)</p></td><td style="vertical-align:top"><p>5.1 (0.6)</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>CL/wt (ml/hr/kg)</p></td><td style="vertical-align:top"><p>12.4 (3.9)</p></td><td style="vertical-align:top"><p>15.9 (2.8)</p></td><td style="vertical-align:top"><p>19.9 (3.4)</p></td></tr></tbody></table><p>Pharmacokinetic parameter values estimated using a model-based approach with sparsely collected pharmacokinetic samples from individual patients in the study.</p><p>*Mean (Standard Deviation) calculated for patients 2 to 6 years of age, since no patients 1 to &lt;2 years of age were enrolled in the study. Simulation using a population pharmacokinetic model demonstrated that the AUCss (area under the concentration-time curve at steady state) of daptomycin in paediatric patients 1 to &lt;2 years of age receiving 12 mg/kg once daily would be comparable to that in adult patients receiving 6 mg/kg once daily.</p><p>Obesity</p><p>Relative to non-obese subjects daptomycin systemic exposure measured by AUC was about 28 % higher in moderately obese subjects (Body Mass Index of 25-40 kg/m2) and 42 % higher in extremely obese subjects (Body Mass Index of &gt; 40 kg/m2). However, no dose adjustment is considered to be necessary based on obesity alone.</p><p>Gender</p><p>No clinically significant gender-related differences in daptomycin pharmacokinetics have been observed.</p><p>Renal impairment</p><p>Following administration of a single 4 mg/kg or 6 mg/kg intravenous dose of daptomycin over a 30- minute period to adult subjects with various degrees of renal impairment, total daptomycin clearance (CL) decreased and systemic exposure (AUC) increased as renal function (creatinine clearance) decreased.</p><p>Based on pharmacokinetic data and modelling, the daptomycin AUC during the first day after administration of a 6 mg/kg dose to adult patients on HD or CAPD was 2-fold higher than that observed in adult patients with normal renal function who received the same dose. On the second day after administration of a 6 mg/kg dose to HD and CAPD adult patients the daptomycin AUC was approximately 1.3-fold higher than that observed after a second 6 mg/kg dose in adult patients with normal renal function. On this basis, it is recommended that adult patients on HD or CAPD receive</p><p>&nbsp;</p><p>daptomycin once every 48 hours at the dose recommended for the type of infection being treated (see section 4.2).</p><p>The dosage regimen for Daptomycin Amarox in paediatric patients with renal impairment has not been established.</p><p>Hepatic impairment</p><p>The pharmacokinetics of daptomycin is not altered in subjects with moderate hepatic impairment (Child-Pugh B classification of hepatic impairment) compared with healthy volunteers matched for gender, age and weight following a single 4 mg/kg dose. No dosage adjustment is necessary when administering daptomycin in patients with moderate hepatic impairment. The pharmacokinetics</p><p>of daptomycin in patients with severe hepatic impairment (Child-Pugh C classification) have not been evaluated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Daptomycin administration was associated with minimal to&nbsp; mild&nbsp; degenerative/regenerative changes in skeletal musclein the rat and dog. Microscopic changes in skeletal&nbsp; muscle&nbsp; were&nbsp; minimal (approximately 0.05 % of myofibres affected) and at&nbsp; the&nbsp; higher&nbsp; doses&nbsp; were&nbsp; accompanied by elevations in CPK. No fibrosis or rhabdomyolysis was observed.&nbsp; Depending on&nbsp; the study duration, all muscle effects, including microscopic changes, were fully reversible within</p><p>1-3 months following cessation of dosing. No functional or pathological changes in smooth or cardiac muscle were observed.</p><p>The lowest observable effect level (LOEL) for myopathy in rats and dogs occurred at exposure levels of 0.8 to&nbsp; 2.3-fold&nbsp; the&nbsp; human&nbsp; therapeutic&nbsp; levels&nbsp; at&nbsp; 6&nbsp; mg/kg&nbsp; (30-minute&nbsp; intravenous&nbsp; infusion) for patients with normal renal function. As the pharmacokinetics (see section&nbsp; 5.2) is&nbsp; comparable, the safety margins for both methods of administration are very similar.</p><p>A study in dogs demonstrated that skeletal myopathy was reduced upon once daily administration as compared to fractionated dosing at same total daily dose, suggesting that myopathic effects in animals were primarily related to time between doses.</p><p>Effects on peripheral nerves were observed at higher doses than those associated with skeletal muscle effects in adult rats and dogs, and were primarily related to plasma Cmax. Peripheral nerve changes were characterised by minimal to slight axonal degeneration and were frequently accompanied by</p><p>&nbsp;</p><p>functional changes. Reversal of both the microscopic and functional effects was complete within 6 months post-dose. Safety margins for peripheral nerve effects in rats and dogs are 8- and 6-fold, respectively, based on comparison of Cmax values at the No Observed Effect Level (NOEL) with the Cmax achieved on dosing with 30-minute intravenous infusion of 6 mg/kg once daily in patients with normal renal function.</p><p>The findings of in vitro and some in vivo studies designed to investigate the mechanism of daptomycin myotoxicity indicate that the plasma membrane of differentiated spontaneously contracting muscle cells is the target of toxicity. The specific cell surface component&nbsp; directly targeted has not been identified. Mitochondrial loss/damage was also observed; however the role&nbsp;&nbsp; and significance of this finding in the overall pathology are unknown. This finding was not associated with an effect on muscle contraction.</p><p>In contrast to adult dogs, juvenile dogs appeared to be more sensitive to peripheral nerve lesions&nbsp; as compared to skeletal myopathy. Juvenile dogs developed peripheral and spinal nerve lesions at doses lower than those associatedwith skeletal muscle toxicity.</p><p>In neonatal dogs, daptomycin caused marked clinical signs of twitching, muscle rigidity in the limbs, and impaired useof limbs, which resulted in decreases in body weight and overall body condition at doses &ge; 50 mg/kg/day and necessitated early discontinuation of treatment in these dose groups. At lower dose levels (25 mg/kg/day), mild andreversible clinical signs of twitching and one incidence of muscle rigidity were observed without any effects on bodyweight. There was no histopathological correlation in the peripheral and central nervous system tissue, or in the skeletal muscle, at any dose level, and the mechanism and clinical relevance for the adverse clinical signs are therefore unknown. Reproductive toxicity testing showed no evidence of effects on fertility, embryofoetal, or postnatal development.However, daptomycin can cross the placenta in pregnant rats (see section 5.2). Excretion of daptomycin into milk oflactating animals has not been studied.</p><p>Long-term carcinogenicity studies in rodents were not conducted. Daptomycin was not mutagenic or clastogenic in abattery of in vivo and in vitro genotoxicity tests.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium Hydroxide and water for injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Daptomycin for injection is not physically or chemically compatible with glucose-containing solutions. This medicinal product must notbe mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 Months
In-Use Storage Conditions for Daptomycin for Injection Once Reconstituted in Acceptable Intravenous Diluents
Stability studies have shown that the reconstituted solution is stable in the vial for 12 hours at room temperature and up to 48 hours if stored under refrigeration between 2° and 8°C (36° and 46°F).
The diluted solution is stable in the infusion bag for 12 hours at room temperature and 48 hours if stored under refrigeration. The combined storage time (reconstituted solution in vial and diluted solution in infusion bag) should not exceed 12 hours at room temperature or 48 hours under refrigeration.
Compatible Intravenous Solutions
Daptomycin for injection is compatible with 0.9% sodium chloride injection and lactated Ringer’s injection.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator between 2&deg;C and 8&deg;C.</p><p>Reconstitution data</p><p>Daptomycin for Injection is compatible with 0.9% sodium chloride injection and lactated Ringer&#39;s injection<strong>.</strong></p><p>For storage conditions after reconstitution and dilution of the medicinal product see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vial pack</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Preparation and Administration of Daptomycin for Injection 350mg/vial</u></strong></p><p><strong>There are different formulations of daptomycin that have differences concerning storage and</strong></p><p>&nbsp;</p><p><strong>reconstitution. Carefully follow the reconstitution and storage procedures in labeling.</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Reconstitution of Daptomycin for Injection Vial</p><p>Daptomycin for injection is supplied in single-dose vials, each containing 350 mg daptomycin as a sterile, lyophilized powder. The contents of a daptomycin for injection vial should be reconstituted, using aseptic technique, to 50 mg per mL as follows:</p><p>1.&nbsp;&nbsp;&nbsp; To minimize foaming, AVOID vigorous agitation or shaking of the vial during or after reconstitution.</p><p>2.&nbsp; Remove the polypropylene flip-off cap from the daptomycin for injection vial to expose the central portion of the rubber stopper.</p><p>3.&nbsp; Wipe the top of the rubber stopper with an alcohol swab or other antiseptic solution and allow to dry. After cleaning, do not touch the rubber stopper or allow it to touch any other surface.</p><p>4.&nbsp;&nbsp; Slowly transfer 7 mL of 0.9% sodium chloride injection through the center of the rubber stopper into the daptomycin for injection vial, pointing the transfer needle toward the wall of the vial. It is recommended that a beveled sterile transfer needle that is 21 gauge or smaller in diameter, or a needleless device is used, pointing the transfer needle toward the wall of the vial.</p><p>5.&nbsp; Ensure that all of the daptomycin for injection powder is wetted by gently rotating the vial.</p><p>i.&nbsp; Allow the wetted product to stand undisturbed for 10 minutes.</p><p>ii..Gently rotate or swirl the vial contents for a few minutes, as needed, to obtain a completely reconstituted solution.</p><p><strong><u>Preparation and Administration of Daptomycin for Injection 500mg/vial</u></strong></p><p><strong>There are different formulations of daptomycin that have differences concerning storage and reconstitution. Carefully follow the reconstitution and storage procedures in labeling.</strong></p><p>Reconstitution of Daptomycin for Injection Vial</p><p>Daptomycin for injection is supplied in single-dose vials, each containing 500 mg daptomycin as a sterile, lyophilized powder. The contents of a daptomycin for injection vial should be reconstituted, using aseptic technique, to 50 mg per mL as follows:</p><p>1.&nbsp;&nbsp;&nbsp; To minimize foaming, AVOID vigorous agitation or shaking of the vial during or after reconstitution.</p><p>&nbsp;</p><p>2.&nbsp; Remove the polypropylene flip-off cap from the daptomycin for injection vial to expose the central portion of the rubber stopper.</p><p>3.&nbsp; Wipe the top of the rubber stopper with an alcohol swab or other antiseptic solution and allow to dry. After cleaning, do not touch the rubber stopper or allow it to touch any other surface.</p><p>4.&nbsp; Slowly transfer 10 mL of 0.9% sodium chloride injection through the center of the rubber stopper into the daptomycin for injection vial, pointing the transfer needle toward the wall of the vial. It is recommended that a beveled sterile transfer needle that is 21 gauge or smaller in diameter, or a needleless device is used, pointing the transfer needle toward the wall of the vial.</p><p>5.&nbsp; Ensure that all of the daptomycin for injection powder is wetted by gently rotating the vial.</p><p>i.&nbsp; Allow the wetted product to stand undisturbed for 10 minutes.</p><p>ii..Gently rotate or swirl the vial contents for a few minutes, as needed, to obtain a completely reconstituted solution.</p><p><strong><u>Administration Instructions</u></strong></p><p>Parenteral drug products should be inspected visually for particulate matter prior to administration. Slowly remove reconstituted liquid (50 mg daptomycin per mL) from the vial using a beveled sterile needle that is 21 gauge or smaller in diameter. Administer as an intravenous injection or infusion as described below:</p><p>Adults</p><p><strong>Intravenous Injection over a period of 2 minutes</strong></p><p>&bull;&nbsp; For intravenous (IV) injection over a period of 2 minutes in adult patients <strong>only</strong>: Administer the appropriate volume of the reconstituted daptomycin for injection (concentration of 50 mg per mL). <strong>Intravenous Infusion over a period of 30 minutes</strong></p><p>&bull;&nbsp; For intravenous (IV) infusion over a period of 30 minutes in adult patients: The appropriate volume of the reconstituted daptomycin for injection (concentration of 50 mg per mL) should be further diluted, using aseptic technique, into a 50 mL IV infusion bag containing 0.9% sodium chloride injection.</p><p>No preservative or bacteriostatic agent is present in this product. Aseptic technique must be used in the preparation of final IV solution. Do not exceed the In-Use storage conditions of the reconstituted and diluted solutions of daptomycin for injection described below. Discard unused portions of</p><p>&nbsp;</p><p>daptomycin for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Saudi Amarox Industrial Company, Aljameah Street, Malaz quarter Riyadh 12629, Saudi Arabia
Tel: +966 11 226 8850

Manufacture: Aspiro Pharma Limited, Hyderabad, India

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Not Applicable.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>